Probiotic bacteria enhance the antibacterial barrier of enterocytes: insights into their mechanism of action by Schlee, Miriam
  
Probiotic Bacteria Enhance the Antibacterial Barrier of  
Enterocytes: Insights into Their Mechanism of Action 
 
 
Dissertation zur Erlangung des Doktorgrades 
der Naturwissenschaften (Dr. rer. nat.) 
 
 
Fakultät Naturwissenschaften 
Universität Hohenheim 
 
 
Institut für Biologische Chemie und Ernährungswissenschaft 
Fachgebiet Ernährungsphysiologie 
Universität Hohenheim 
Prof. Dr. Ch. Bode 
 
 
Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie 
Robert Bosch Krankenhaus 
Prof. Dr. E. F. Stange 
 
 
 
vorgelegt von 
Miriam Schlee 
 
    aus München 
2006
   II 
The studies underlying this work were carried out at the Dr. Margarete Fischer-Bosch In-
stitute of Clinical Pharmacology in Stuttgart in the laboratory group of Prof. E. F. Stange 
and supported by the Robert Bosch Foundation.  
 
 
 
 
 
 
 
 
 
 
Dekan:    Prof. Dr. H. Breer 
1. berichtende Person:  Prof. Dr. Ch. Bode 
2. berichtende Person:  Prof. Dr. E. F. Stange 
3. Prüfer:   Prof. Dr. H. Schmidt 
Eingereicht am:  20.11.06 
Mündliche Prüfung am: 23.02.07 
 
 
 
 
 
 
 
 
 
 
Die vorliegende Arbeit wurde am 23.02.07 von der Fakultät Naturwissenschaften der Uni-
versität Hohenheim als „Dissertation zur Erlangung des Doktorgrades der Naturwissen-
schaften“ angenommen. 
   III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Great works are performed, not by strength, but by perseverance. He that shall walk, with 
vigor, three hours a day, will pass, in seven years, a space equal to the circumference of the 
globe.        
         Samuel Johnson (1709-84), English poet 
 
   IV 
TABLE OF CONTENTS 
Abbreviations 
Summary 
Zusammenfassung 
1 INTRODUCTION ............................................................................................................. 1 
1.1 The composition and benefits of the normal flora .................................................... 1 
1.2 Etiology, pathophysiology and the role of the luminal flora in IBD ........................ 3 
1.3 Probiotics – Definition and characteristic traits ........................................................ 7 
1.3.1 Prophylactic or therapeutic application of probiotics ..................................... 9 
1.4 Defensins – genetics, expression and regulation..................................................... 11 
1.4.1 Mechanisms of activity of defensins ............................................................ 13 
1.4.2 Association of a dysregulated defensin expression with diseases ................ 16 
1.5 Signalling pathways involved in the innate immune response ............................... 18 
1.6 The E. coli strain Nissle and its characteristics....................................................... 22 
3 OBJECTIVES ................................................................................................................ 24 
4 MATERIAL AND METHODS ......................................................................................... 25 
4.1 Material ................................................................................................................... 25 
4.1.1 Chemicals and reagents ................................................................................ 25 
4.1.2 General material............................................................................................ 26 
4.1.3 General technical tools ................................................................................. 26 
4.1.4 Standards....................................................................................................... 27 
4.1.5 Protein, enzymes and peptides...................................................................... 27 
4.1.6 Antibodies..................................................................................................... 28 
4.1.7 Buffers and solutions for SDS-PAGE and Western blot analysis ................ 28 
4.1.8 Reagents and solutions for isolation and analysis of RNA........................... 29 
4.1.9 Plasmids and oligonucleotides...................................................................... 29 
4.1.10 Commercial Kits ........................................................................................... 31 
4.2 Methods................................................................................................................... 32 
4.2.1 Cell cultivation.............................................................................................. 32 
4.2.2 Preparation of human PBMC´s..................................................................... 34 
4.2.3 TLR spectrum ............................................................................................... 34 
4.2.4 Bacteria cultivation....................................................................................... 35 
4.2.5 Molecularbiological methods ....................................................................... 38 
4.2.6 Methods to determine the hBD-2 inducing factor from E. coli Nissle ......... 43 
4.2.7 IL-8 ELISA................................................................................................... 48 
4.2.8 HBD-2 purification from cell culture supernatant for hBD-2 ELISA.......... 48 
4.3 Statistical evaluation ............................................................................................... 48 
   V 
5 RESULTS ..................................................................................................................... 49 
5.1 Expression studies in colonic epithelial cells.......................................................... 49 
5.1.1 Differential human beta defensin-2 and IL-8 expression ............................. 49 
5.1.2 Toll-like receptors......................................................................................... 50 
5.2 Time- and dose-dependent hBD-2 mRNA expression............................................ 51 
5.2.1 Induction by IL-1β ........................................................................................ 51 
5.2.2 Expression of hBD-2 by Caco-2 cells as a function of cell differentiation .. 52 
5.2.3 HBD-2 induction by different probiotic strains............................................ 53 
5.2.4 Induction of hBD-2 by culture supernatant of E. coli Nissle........................ 56 
5.3 Transcriptional regulation and signalling pathways of hBD-2 gene expression 
induced by probiotics....................................................................................................... 59 
5.3.1 Role of the transcription factors NF-κB and AP-1 ....................................... 59 
5.3.2 Role of MAP kinases in probiotic cell signalling......................................... 62 
5.4 Determination of the hBD-2 inducing factor of E. coli Nissle ............................... 65 
5.5 Identification and isolation of the bacterial hBD-2 inducing factor ....................... 70 
6 DISCUSSION ................................................................................................................ 75 
6.1 Different cell lines as a model to investigate hBD-2 expression ............................ 75 
6.2 TLR expression ....................................................................................................... 76 
6.3 Time- and dose-dependent hBD-2 expression in Caco-2 cells ............................... 77 
6.4 Bacterial supernatant is more potent than bacterial pellet to induce hBD-2........... 78 
6.5 Transcriptional regulation of hBD-2 expression by probiotics............................... 79 
6.6 Signalling pathways involved in hBD-2 expression mediated by probiotics ......... 81 
6.7 Analysis of the hBD-2 inducing factor in the E. coli Nissle supernatant ............... 83 
6.7.1 LPS ............................................................................................................... 83 
6.7.2 Immunostimulatory bacterial DNA .............................................................. 85 
6.7.3 Heat and proteinase treatment....................................................................... 86 
6.7.4 Mutant E. coli Nissle strains ......................................................................... 86 
6.8 Outlook.................................................................................................................... 91 
7 REFERENCES ............................................................................................................... 94 
8 PUBLICATIONS .......................................................................................................... 115 
9 ACKNOWLEDGEMENTS.............................................................................................. 117 
10 CURRICULUM VITAE.................................................................................................. 119 
11 APPENDIX ................................................................................................................. 120 
Abbreviations   VI 
LIST OF ABBREVIATIONS 
AIDA Advanced Image Data Analyser 
AMP Antimicrobial peptide 
AP-1 Activator protein 1 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
bp Base pairs 
BSA Bovine serum albumine 
Caco-2 Colon adenocarcinoma cells 
CD Crohn´s Disease 
CD8 Coreceptor of cytotoxic T cell receptor 
cDNA Complementary desoxyribonucleic acid 
CF Cystic fibrosis 
CFU Colony forming units 
CpG Deoxycytidylate-phosphate-deoxyguanylate 
DEPC Diethylpyrocarbonate 
DMEM Dulbecco Modified Eagle Medium 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbant assay 
ERK Extracellular signal-regulated kinase 
Fig. Figure 
GAPDH Glycerylaldehyde-phospho-dihydrogenase 
GIT Gastrointestinal tract 
GM-CSF Granulocyte macrophage-colony-stimulating factor 
hBD Human beta defensin 
HBSS-CMF Hanks balanced salt solution – Ca2+ and Mg2+ free 
HD Human defensin 
HEPES Hydroxyethylpiperazine-N`-ethanesulfonic acid 
HNP Human neutrophil peptide 
HRP Horseradish peroxidase 
IBD Inflammatory bowel disease 
IEC Intestinal epithelial cell 
IFN Interferon 
IgA Immunglobulin A 
IL Interleukin 
Abbreviations   VII 
IRAK Interleukin-1 receptor-associated kinase 
JNK c-Jun N-terminal kinase 
kD Kilo Dalton 
LDL Low density lipoprotein 
LPS Lipopolysaccharide 
M Mol/l 
MAPK Mapkinase 
MOPS 3-(N-Morpholino)-propanesulfonic acid 
mRNA Messenger ribonucleic acid 
MRSA Methicillin-resistent Staphylococcus aureus 
MTT 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazolium bromide) 
MWCO Molecular weight cut off 
NF-IL-6 Nuclear factor of interlukin 6 
NF-κB Nuclear factor kappa B 
ODN Oligodeoxynucleotides 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PMA Phorbolmuramylacetate 
RNA Ribonucleic acid 
rpm Rounds per minute 
RPMI Roswell Park Memorial Institute 
RT-PCR Reverse transcription-polymerase chain reaction 
sp. Subspecies (bacteria) 
STAT Signal Transducer and Activator of Transcription 
TAE Tris/Acetic acid/EDTA 
TEMED Tetramethylethylenediamin 
TGF Transforming growth factor 
Th1 Inflammatory T cells type I 
Th2 T-helper cells type II 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRAF6 TBF-receptor-associated factor 6 
TRIS Tris-(hydroxymethyl-)methylamine 
UC Ulcerative colitis 
v/v Volume per volume 
w/v Weight per volume 
X-Gal 5-brom-4-chlor-indolyl-ß-galactopyranoside 
 
Summary   VIII 
SUMMARY 
In the healthy intestine there is a stable balance of luminal bacteria and host factors to pre-
vent infections or inflammatory bowel diseases (IBD). A complex network of environ-
mental, genetic, and immunoregulatory factors may precipitate the onset of ulcerative coli-
tis (UC) and Crohn's disease (CD), the primary manifestations of inflammatory bowel dis-
ease (IBD). It is currently believed that IBD results from an aberrant immune response of 
the intestinal mucosa towards the normal commensal bacterial flora. Alternatively, a pri-
mary defect in the mucosal barrier might permit bacterial invasion and trigger inflamma-
tion. In our research group the hypothesis was proposed that the defective barrier in 
Crohn´s disease may be due to a lack of defensins which form a chemical barrier against 
luminal bacteria. 
 
A major gut defensin is the human beta defensin-2 (hBD-2) which is an inducible antim-
icrobial peptide synthesized and secreted by the epithelium to counteract bacterial adher-
ence and invasion. Proinflammatory cytokines, as well as certain bacterial strains, have 
been identified as potent endogenous inducers. In recent studies, Fellermann et al demon-
strated that the defective expression of hBD-2 which was measured in the gut mucosa of 
patients with Crohn´s disease was due to a reduced copy number of the hBD-2 gene. In 
patients with ulcerative colitis β-defensin expression is low in the colon during remission, 
but readily inducible during inflammation. Probiotic bacteria might act beneficially in the 
human gut by inducing the expression of defensins and thereby reinforcing the mucosal 
barrier. Recently, our group has been the first to describe hBD-2 induction by the probiotic 
strain E. coli Nissle (Mutaflor®) which is an effective treatment for ulcerative colitis during 
remission. 
 
The aim of the present work was to determine the underlying molecular mechanisms. We 
determined a time- and dose-dependent expression pattern of hBD-2 in Caco-2 cells upon 
stimulation with IL-1β, E. coli Nissle culture supernatant and diverse other probiotic 
strains. We further investigated the transcriptional regulation of hBD-2 expression medi-
ated by probiotics. The hBD-2 promoter contains several elements known to be involved in 
transcriptional upregulation such as the NF-κB element, which is believed to be one of the 
main regulators of the hBD-2 gene expression. However, for certain signals, the expression 
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of the hBD-2 gene has been reported to depend on the activation of a second transcription 
factor, such as AP-1. Most importantly, E. coli Nissle was shown to shed or secrete factors, 
contained in the bacterial supernatant, which were sufficient to trigger activation of NF-κB 
and AP-1 and to induce hBD-2. Our results indicated further that the supernatant-induced 
activation of the MAP kinase pathways ERK½, JNK, and p38 may be directly responsible 
for the probiotic supernatant-induced activation of the transcription factors AP-1 and NF-
κB and subsequent synthesis of hBD-2.  
 
A further aim of the present study was to identify and isolate the bacterial components 
which are responsible for E. coli Nissle mediated hBD-2 induction. As E. coli Nissle cul-
ture supernatant was found to be a more potent stimulant than the bacterial pellet, we in-
vestigated the characteristics of the unknown soluble or shed molecules in the bacterial 
culture media. The first analysis revealed the factor as a heat resistant and proteinase sensi-
tive molecule. Both, E. coli Nissle specific lipopolysaccharide (LPS) and bacterial DNA, 
which might contain immunostimulatory DNA motifs, failed to trigger hBD-2 expression.  
 
Based on the knowledge of the surface composition several E. coli Nissle deletion mutants 
were constructed and tested for their ability to induce hBD-2 expression in Caco-2 cells. 
Deletion mutants for flagellin, the flagella filament protein, specifically exhibited an im-
paired immunostimulatory capacity. Reinsertion of the flagellin gene restored the induction 
capacity to normal levels. Next, we isolated flagellins from different bacteria strains (Sal-
monella enterica serovar Enteritidis, E. coli ATCC 25922, E. coli Nissle and the uropatho-
genic E. coli strain CFT073∆hly, whose genome structure resembles closely that of E. coli 
Nissle). In the Western blot anti-H1 flagellin displayed immunoreactivity against the dif-
ferent types of flagellins, due to the highly conserved central region of the flagellin fila-
ment structure.  
 
Incubation of Caco-2 cells with isolated E. coli Nissle flagellin (molecular size 60.81 kDa) 
induced hBD-2 promoter activation in a dose-dependent manner. The induction of hBD-2 
expression by flagellin was confirmed with a positive control (Salmonella flagellin). Inter-
estingly, the serotype-identical CFT073∆hly flagellin expressed only moderate hBD-2 in-
ducing ability compared to E. coli Nissle flagellin. Thus, differences in extracellular matrix 
Summary   X 
e.g. the glycosilation degree might underlie the differentially modulated hBD-2 response of 
Caco-2 cells by the two flagellins. H1 flagellin antiserum abrogated hBD-2 expression 
induced by flagellin as well as E. coli Nissle supernatant, confirming that flagellin is the 
major stimulatory factor of E. coli Nissle.  
 
In conclusion, flagellin of E. coli Nissle provides reinforcement of mucosal antimicrobial 
function, apparently without inducing inflammation. This might explain the beneficial ef-
fects of E. coli Nissle on remission maintenance in ulcerative colitis. In patients with 
Crohn´s disease there is evidence against a therapeutic effect of probiotics and this may be 
explained by a defective defensin system. Future investigations about strain-specific bene-
ficial functions might contribute to the therapeutic application of science-based probiotic 
products. 
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ZUSAMMENFASSUNG 
Im gesunden Darm herrscht ein stabiles Gleichgewicht zwischen der luminalen Flora und 
körpereigenen Abwehrkräften, das Infektionen oder entzündlichen Erkrankungen im Darm 
vorbeugt. Ein komplexes Netzwerk aus Umwelteinflüssen, genetischen und immunregula-
torischen Faktoren kann den Ausbruch von Colitis ulcerosa oder Morbus Crohn, den 
Haupterscheinungsformen der chronisch entzündlichen Darmerkrankungen (CED) herbei-
führen. Eine überschießende Immunantwort der intestinalen Epithelzellen gegenüber der 
normalen Darmflora wird als auslösender Faktor für  die intestinale Entzündung postuliert. 
Alternativ, könnte auch ein Primärdefekt der mukosalen Barriere verantwortlich für eine 
bakterielle Invasion und die darauffolgende Entzündung sein. In unserer Arbeitsgruppe 
wurde vor kurzem die Hypothese entwickelt, dass die gestörte Darmbarrierefunktion bei 
Morbus Crohn in einem Mangel an Defensinen begründet sein könnte, welche eine Art 
chemische Barriere gegen luminale Bakterien darstellen. 
 
Eines der wichtigsten Defensine des Darms ist das humane beta Defensin-2 (hBD-2) wel-
ches ein, durch proinflammatorische Zytokine sowie spezielle Bakterienstämme induzier-
bares, antimikrobiell wirksames Peptid ist. Es wird von Epithelzellen synthetisiert und se-
zerniert zur Abwehr einer bakteriellen Adhärenz und Invasion. Fellermann et al wies vor 
kurzem nach, dass die in der Darmschleimhaut des Kolons von Morbus Crohn Patienten 
gemessene defekte hBD-2 Expression durch eine verringerte Genkopienzahl des humanen 
beta-Defensins-2 bedingt ist. Bei Patienten mit Colitis ulcerosa ist die β-Defensin Expres-
sion im Kolon in der beschwerdefreien Phase (=Remission) niedrig, in der Entzündung 
wird diese jedoch umgehend induziert. Probiotika könnten durch eine Induktion der Defen-
sinexpression im Darm einen günstigen Einfluss ausüben und somit die Darmbarriere stär-
ken. 
 
Unsere Arbeitsgruppe hat vor kurzem erstmals eine hBD-2 Induktion durch den probioti-
schen Keim E. coli Nissle (Mutaflor®) nachgewiesen, der mit gutem Behandlungserfolg in 
der Remission der Colitis ulcerosa Einsatz findet. Das Ziel der vorliegenden Arbeit war, 
die zugrunde liegenden molekularen Mechanismen zu untersuchen. Wir bestätigten ein 
zeit- und dosisabhängiges hBD-2 Expressionsmuster in Caco-2 Zellen durch Stimulation 
mit IL-1β, E. coli Nissle Kulturüberstand und diversen anderen probiotischen Keimen.  
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Des Weiteren untersuchten wir die transkriptionelle Regulation der probiotika-vermittelten 
hBD-2 Expression. Der hBD-2 Promotor enthält verschiedene, an der Aktivierung der 
Transkription beteiligte Elemente, wie z.B. dem nukleären Faktor NF-κB welches ein 
Hauptregulator der hBD-2 Expression zu sein scheint. Es gibt jedoch Hinweise darauf, 
dass die Expression des hBD-2 Gens durch gewisse Stimulanzien noch von einem weiteren 
Transkriptionsfaktor abhängt, wie z.B. AP-1. Sezernierte oder abgelöste Faktoren des E. 
coli Nissle, welche sich im Kulturüberstand befinden, waren ausreichend in der Lage hBD-
2 durch die Aktivierung von NF-κB und AP-1 zu induzieren. Die überstandsinduzierte 
Aktivierung der MAP-Kinase-Signalwege über ERK½, JNK und p38 scheint hierbei direkt 
verantwortlich zu sein für die über AP-1 und NF-κB aktivierte Synthese von hBD-2. 
 
Ein weiteres Ziel dieser Arbeit war die Identifizierung und Isolation der bakteriellen Be-
standteile des E. coli Nissle welche für die hBD-2 Induktion verantwortlich sind. Da der 
Bakterienkulturüberstand ein stärkerer Stimulus als das Bakterienpellet war, untersuchten 
wir die Charakteristiken der unbekannten löslichen oder abgegebenen Moleküle im bakte-
riellen Kulturmedium. Erste Untersuchungen ergaben, dass der gesuchte Faktor eine hitze-
resistente, durch Proteinase verdaubare Komponente des Bakteriums darstellt. Das für E. 
coli Nissle spezifische Lipopolysaccharid (LPS) sowie dessen bakterielle DNA, welche 
immunstimulatorische DNA-Motive enthalten könnte, hatten keinen hBD-2 induzierenden 
Einfluss.  
 
Auf der Grundlage bekannter oberflächlich exprimierter Moleküle des E. coli Nissle wur-
den mehrere Deletionsmutanten konstruiert und auf ihre Fähigkeit, die hBD-2 Expression 
in Caco-2 Zellen auszulösen, untersucht. Flagellin-Deletionsmutanten wiesen eine stark 
verminderte immunstimulatorische Kapazität auf. Das erneute Einfügen des deletierten 
Flagellingens regenerierte die Fähigkeit zur hBD-2 Induktion vollständig. Des Weiteren 
isolierten wir Flagellen aus verschiedenen Bakterienstämmen (Salmonella enterica serovar 
Enteritidis, E. coli ATCC 25922, E. coli Nissle und dem uropathogenen E. coli Stamm 
CFT073∆hly, dessen Genom dem des E. coli Nissle sehr ähnlich ist). Im Western Blot 
wurde eine Immunreaktivität von Anti-H1 Flagellin gegen die verschiedenen Flagellinty-
pen nachgewiesen, was sich durch die hoch konservierte Zentralregion der Flagellinfila-
mentstruktur erklären lässt.  
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Die Inkubation von Caco-2 Zellen mit dem isolierten E. coli Nissle Flagellin (Molekular-
gewicht: 60.81 kDa) induzierte dosisabhängig die hBD-2 Promotoraktivierung. Die Induk-
tion der hBD-2 Expression durch Flagellin wurde mit einer Positivkontrolle (Salmonella 
Flagellin) bestätigt. Interessanterweise war die Induzierbarkeit durch das serotypidentische 
CFT073∆hly Flagellin, verglichen mit der des E. coli Nissle Flagellins reduziert. Unter-
schiede in der Extrazellulärmatrix, z.B. dem Glykosilierungsgrad, könnten die verschieden 
ausgeprägte hBD-2 Antwort der Caco-2 Zellen auf die beiden Flagelline erklären. Zusätz-
lich wurde die Flagellin- und E. coli Nissle Überstand-induzierte hBD-2 Expression durch 
H1-Flagellin Antiserum gehemmt. Diese Befunde lassen schließen, dass Flagellin der 
hauptverantwortliche Faktor für die Stimulation der hBD-2 Expression durch E. coli Nissle 
ist. 
 
Das Flagellin des E. coli Nissle stärkt somit die mukosale antimikrobielle Funktion des 
Darmepithels ohne eine Entzündung auszulösen. Dies könnte die positive Wirkung des E. 
coli Nissle auf die Remissionserhaltung der Colitis ulcerosa erklären. Bei Patienten mit 
Morbus Crohn gibt es Hinweise gegen einen therapeutischen Nutzen von Probiotika, was 
durch ein defektes Defensinsystem erklärt werden könnte. Die Charakterisierung positiver 
Eigenschaften relevanter Keime könnte einen Beitrag zur evidenz-basierten therapeuti-
schen Verwendung probiotischer Produkte liefern.  
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1 INTRODUCTION 
1.1 The composition and benefits of the normal flora 
The human gastrointestinal tract (GIT) is colonized by a remarkable community of symbi-
onts and commensals performing an essential role in nutrient processing as well as innate 
and adaptive immunity. Approximately 500 different species of microorganisms exert a 
metabolic activity comparable to that of the liver (Berg 1996; Bocci 1992). Differences in 
the composition of the flora are influenced by age, diet, cultural conditions, and the use of 
antibiotics. In the upper gastrointestinal tract of adults, the oesophagus contains only the 
bacteria swallowed with saliva and food (Fig. 1).  
 
Due to the high acidity of the gastric juice, very few types of bacteria (mainly acid-tolerant 
lactobacilli) can be cultured from the normal stomach. However, the infestation of the 
stomach with the pathogenic bacterium Helicobacter pylori is one of the most common 
infectious diseases worldwide known to cause peptic ulcer disease, and probably also gas-
tric cancer (Stolte 1998; Todar 2002). 
 
 
 
 
Figure 1: Bacteria distribution in the gastrointestinal tract. CFU, colony forming units (Source: 
www.agen.ufl.edu/~chyn/age2062/lect/lect, right panel adapted from Otte 2003) 
Oesophagus
1. Oral cavity:  
Saliva: 109 CFU/ml 
Dental plaque: 1011 CFU/g 
3. Stomach / duodenum 
101-103 CFU/ml,  
Helicobacter pylori 
4. Jejunum / ileum 
104-108 CFU/ml 
5. Colon 
1010-1012 CFU/g 
2. Oesophagus 
Streptococcus viridans, 
Candida albicans 
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The proximal small intestine is populated by a relatively sparse, gram-positive flora con-
sisting mainly of lactobacilli and Enterococcus faecalis. The distal part of the small intes-
tine contains higher concentrations of bacteria (108/ml) and additional species including 
coli forms and Bacteroides, next to lactobacilli and enterococci. The flora of the large in-
testine (colon) is qualitatively similar to that found in faeces. In the colon, with 1011 bacte-
ria/ml faeces, coliforms become more prominent and enterococci, clostridia and lactoba-
cilli can be regularly found, but the predominant species are anaerobic Bacteroides and 
anaerobic lactic acid bacteria of the genus Bifidobacterium (Todar 2002). 
 
At birth, the entire intestinal tract is sterile, but following delivery, multiple different anti-
gens challenge the intestine of the newborn and the maternal intestinal flora is a major 
source of bacteria for the neonatal gut. After the first week of life, a stable bacterial flora is 
usually established (Fanaro 2003). In breast-fed infants, bifidobacteria account for more 
than 90 % of the total intestinal bacteria as opposed to the bacterial distribution found in 
bottle-fed infants where other bacteria such as bacteroides, enterococci or clostridia pre-
vail. Apparently, human milk contains a growth factor that enhances the growth of bifido-
bacteria which play an important role in preventing colonization of the infant intestinal 
tract by non-indigenous or pathogenic species. 
 
The indigenous bacteria of the gastrointestinal tract, mainly because of their enormous 
number, seem to have the greatest overall impact on their host. To understand the conse-
quences of a disturbed flora it is important to know more about the beneficial effects of the 
normal flora. 
 
Benefits of the host’s indigenous flora: 
¾ Colonization with pathogens is prevented by competition for attachment sites or for 
essential nutrients (Goldin 1998) 
¾ Bacteria are antagonized. This may occur through the production of highly specific 
bacteriocins, which inhibit or kill nonindigenous species (Riley 2002 ) 
¾ Bacteria synthesize and excrete vitamins in excess of their own needs, which can be 
absorbed as nutrients by the host, e.g. enteric bacteria secrete Vitamin K and sev-
eral B vitamins such as Vit. B12 (Hill 1997) 
Introduction   3 
¾ Development of the gut-associated lymphoid tissues is stimulated (Rhee 2004) 
¾ Production of cross-reactive antibodies is stimulated. Low levels of antibodies pro-
duced by the normal flora are known to crossreact with certain pathogens and 
thereby prevent infection or invasion by pathogenic strains (Wijburg 2006). 
 
1.2 Etiology, pathophysiology and the role of the luminal flora in IBD 
There is increasing evidence that the balance of the luminal flora also plays a critical role 
in the initiation and perpetuation of colitis. The incidence of “non-specific” inflammatory 
bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn´s disease (CD), 
once regarded as medical curiosities, has increased sharply in the late 1900s and now af-
fects millions of people worldwide. The specific type of IBD can be difficult to distinguish 
because the symptoms are often similar. The acute clinical characteristics are diarrhoea, 
abdominal pain, fever and weight loss; the acute pathologic features include a constant flux 
of neutrophils into inflamed mucosa, eventually penetrating the epithelium into the intesti-
nal lumen. Crohn´s disease may affect the entire length of the gastrointestinal tract but 
preferentially manifests in the terminal ileum, as was originally described by Crohn et al 
(1932). Ulcerative colitis is usually restricted to the colon where inflammation appears to 
be continuous.  
 
Since the etiology of ulcerative colitis and of Crohn´s disease remains elusive, many unre-
solved aspects of the pathogenesis of IBD are matters of investigation including: environ-
mental factors, emerging new types of bacteria, the body’s defences against bacteria and 
viruses, psychoneuro-immunological, genetic and neurohormonal mechanisms mediating 
stress and emotional disturbances (Kirsner 2001).  
Genetic factors 
Familial distributions of IBD involved first-degree relatives more often than second- or 
third-degree relatives (Orholm 1991). Sartor (1998) suggested that a genetically deter-
mined, overly aggressive immune response to ubiquitous resident luminal bacterial con-
stituents might be the cause for chronic intestinal inflammation. This dysfunctional re-
sponse could be mediated by either defective immunoregulatory events and/or abnormal 
epithelial barrier function. 
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Genetic research programs have identified single nucleotide polymorphisms in the coding 
region of the bacterial sensing gene NOD2 (IBD1 locus on chromosome 16) with a suscep-
tibility to ileal Crohn´s disease (Hampe 2001; Ogura 2001; Hugot 2001). Between 17-25 % 
of Crohn´s disease patients carry mutations in the NOD2/CARD15 gene resulting in de-
creased NF-κB expression, which might alter the host’s immune response to the bacterial 
flora (Hampe 2001). Several other loci are associated with either UC or CD while others 
are involved in the pathogenesis of both IBD forms (Ahmad 2004). Genetic variation in 
other innate immune receptors, notably the Toll-like receptor (TLR) 4, has been defined 
and may also play a role in CD pathogenesis (Brand 2005).  
 
Furthermore, Fellermann et al (2006) determined a reduced gene copy number of the hu-
man beta defensin-2 (hBD-2) in colonic CD but not in ileal CD, UC or controls. Thus a 
low hBD-2 gene copy number creates a predisposition to colonic CD. The human leuko-
cyte antigen (HLA) class II genes are also candidates in the pathogenesis of IBD as their 
products play a central role in the immune response. However, they may play a greater role 
as disease phenotype modifiers than in determining overall disease susceptibility (Satsangi 
1996).  
Immunological factors 
Both ulcerative colitis and Crohn´s disease are characterized by an increased expression of 
“general” proinflammatory cytokines (TNF-α, IL-1, IL-6), which suggests an abnormally 
intense inflammatory response to commensal bacteria. This loss of immune tolerance to 
non-pathogenic microbes results in pathologic immune reactivity and a self-supporting 
inflammatory cascade. A role for cytokines is also indicated by favourable clinical re-
sponses to blockage of them, for instance by anti-IL-12 thereby enhancing the epithelial 
barrier and inhibiting proinflammatory cytokines.  
Microbiological factors 
Several studies provide substantial evidence that the normal enteric flora plays a key role 
in the development of IBD. In the majority of IBD animal models, intestinal inflammation 
fails to develop when the animals are raised in a germfree environment. For example, inter-
leukin-2 (IL-2) - or interleukin-10 (IL-10) -deficient mice spontaneously develop colitis 
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under conventional housing conditions, which is highly attenuated under germfree condi-
tions (Ehrhardt 1997; Sellon 1998). Similarly, T-cell receptor knock-out mice fail to de-
velop colitis in the absence of normal bacteria (Dianda 1997).  
 
Changes in the normal flora of IBD patients, more precisely high numbers of unusual bac-
teria, reduced biodiversity and a generalized or localized dysbiosis have been reported fre-
quently (Ott 2004; Seksik 2006). More than 50 years ago Seneca et al (1950) determined 
already an 85-fold increase compared to healthy individuals in the total number of micro-
organisms and a fifty-fold increase in the numbers of coliforms in the stools of patients 
with severe ulcerative colitis. They postulated that the large number of bacteria created 
damaging proteolytic enzymatic activity, which injured the intestinal mucosa and was fol-
lowed by secondary bacterial infection.  
 
Several studies were carried out to find possible pathogenic characteristics of E. coli organ-
isms in ulcerative colitis. The isolated coliforms from patients with ulcerative colitis had a 
higher incidence of in vitro adhesive and invasive properties compared to controls (Dickin-
son 1980). The UC strains also included a higher proportion of coliforms that produced 
hemolysin and necrotoxin and caused a severe tissue reaction in segments of rabbit ileum 
(Cooke 1974; Cooke 1968). In jejunum, ileum and colon resectates from Crohn´s disease 
patients an abnormal ileal flora was inferred by the detection of increased amounts in E. 
coli and Bacteroides fragilis in the ileum (Keighley 1978). The latter strain was found to be 
responsible for >60% of the mucosal biofilm mass in IBD patients but only for 30% in 
patients with self-limiting colitis and <15% of the biofilm mass in patients with inflamma-
tory bowel syndrome (Swidsinski 2005).  
 
Swidsinski et al reported that mucosal bacteria concentrations progressively increase from 
self-limiting colitis to indeterminate colitis with the highest amounts of bacteria found in 
Crohn´s disease patients compared to the virtually sterile mucosal surface of healthy con-
trols. However, he did not observe any difference in the composition of the mucosal flora 
in patients with inflammatory bowel disease or in controls (Swidsinski 2002).  
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At sites of inflammation, bacteria may encounter dysfunctional or absent epithelium, with 
gross changes to the barriers that normally attenuate invasion and exposure of stromal sites 
for bacterial adhesion (Braun 2002). Darfeuille-Michaud et al (1998) hypothesized that 
entero-adherent E. coli strains in ileal mucosa might disrupt the intestinal barrier by syn-
thesizing alpha-hemolysin. Swidsinski et al (2005) however uncovered little evidence for 
these modes of bacterial invasion and hypothesized that crossing of mucus barriers and 
bacterial adhesion would occur in advance of mucosal destruction.  
 
Research focussed for some time on the identification of possible agents responsible for 
IBD such as mycobacteria (Mycobacterium avium paratuberculosis (Chiodini 1984)), bac-
terial components (e.g., lipopolysaccharides, peptidoglycans), metabolic products (en-
dotoxins) and the host intestinal bacteria, but none of the investigations confirmed a role 
for specific factors related to CD or UC. The apparent rarity of IBD in third world coun-
tries with a high incidence of specific intestinal infections and parasitic infestations is of 
particular interest. Interestingly, mice previously exposed to helminthic infestations (a 
worm classified as a parasite) apparently are protected against experimentally-induced in-
testinal inflammation (Elliott 2003) via a helminth-induced mucosal Th2 response (Shi 
1998). Recently, disease activity was also shown to be diminished in IBD patients after 
exposure to the helminth Trichuris suis (Elliott 2005; Summers 2005).  
 
An attempt to correlate inflammatory bowel disease and domestic hygiene in infancy (Gent 
1994) was made in England including 364 IBD patients with matched controls (133 CD 
and 231 UC patients). “Evidence” of a “sanitized” environment was taken as the availabil-
ity of a hot water tap and bathroom in the childhood home. While the results supported the 
hypothesis of delayed early exposure to enteric infections as a contributing factor in the 
development of Crohn´s disease (not ulcerative colitis), the limitations of this study are 
apparent.  
 
The frequent onset of IBD following an acute enterocolonic infection (e.g., traveller’s diar-
rhoea) might suggest the implication of a food- or waterborne microbial agent despite the 
lack of evidence that either CD or UC are classical infectious diseases i.e. the aquisition of 
a specific pathogen by direct contact with a patient. Multiple bacterial species are appar-
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ently involved in the onset of IBD, but rather as precipitants of the tissue reaction, modi-
fied by genetic and immune influences, than as direct causes of inflammation. This hy-
pothesis is supported by clinical observations that a reduction of intestinal bacterial con-
centrations by various techniques could lead to clinical improvement and diminished intes-
tinal inflammation (Sellon 1998). Rutgeerts et al (1991) reported that the recurrence of an 
inflammation in the neoterminal ileum of Crohn´s disease patients after resection of the 
distal ileum correlated with the contact of bacteria in the faeces. If the fecal stream was 
diverted via terminal ileostomy, biopsies from the patients showed no inflammatory 
changes characteristic to CD.  
Epithelial permeability 
Finally, the role of bacteria in the pathogenesis of IBD is further confirmed by an increased 
intestinal permeability in CD patients, suggesting an enhanced entry of bacteria and bacte-
rial products into the intestinal wall, initiating or aggravating an inflammatory response 
(Hollander 1986). An association between IBD and genes which are involved in mucosal 
transport and integrity (e.g., the novel organic cation transporter OCTN or DGL5) has been 
reported recently (Vermeire 2006), supporting the assumption of an increased permeability 
preceding the onset of symptomatic disease (Wyatt 1993). 
 
1.3 Probiotics – Definition and characteristic traits 
The microbiological aspects of IBD have also renewed interest in the potential therapeutic 
benefits of stabilising the normal intestinal microflora by probiotics (e.g., Lactobacillus 
sp., Bifidobacterium sp., Streptococcus sp., and the yeast Saccharomyces boulardii) as 
adjuncts to conventional treatment (Campieri 1999).  
 
Probiotics have been defined after several revisions as follows: “A preparation of or a 
product containing viable, defined microorganisms in sufficient numbers, which alter the 
microflora (by implantation or colonization) in a compartment of the host and by that exert 
beneficial health effects in this host” (Schrezenmeir 2001). The consumption of “probiot-
ics” originates centuries before any theoretical understanding of possible mechanisms of 
action. A Persian version of the Old Testament (Genesis 18:8), states, that “Abraham owed 
his longevity to the consumption of sour milk” (Schrezenmeir 2001).  
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The Roman historian Plinius recommended in 76 BC the administration of fermented milk 
products for the treatment of gastroenteritis (Bottazzi 1983). 
 
The theoretical concept of probiotics was first described by the Russian Nobel-prize-holder 
E. Metchnikoff in the early 20th century. He noted that people in Bulgaria, considered as 
“underdeveloped”, had a higher life expectancy than people in other countries. Metch-
nikoff (1907) claimed that the intake of yogurt containing lactobacilli (e.g., Lactobacillus 
bulgaricus) created a hostile environment for pathogens by the production of acid, leading 
to a reduction of toxin-producing bacteria in the gut. The euphoria surrounding this claim 
soon decreased after scientists proved the lack of resistance to gastric acid and bile salts of 
the classic strains Lactobacillus bulgaricus and Streptococcus thermophilus found in yo-
ghurt. Probiotics regained interest with the observation that lactobacilli or bifidobacteria 
strains survive the transport through the gastrointestinal tract (Rettger 1935). 
 
Microorganisms need to meet the following criteria to be considered probiotic: 
• Safety: no pathogenic effect may result from the use of specific bacterial strains 
• Survival of the gastrointestinal passage (bile and acid resistance) 
• Capacity to adhere to the mucosal epithelium of the GIT 
• Metabolic activity in the gastrointestinal tract (GIT), implies colonization 
• Antimicrobial activity against pathogenic bacteria 
• Sufficient germ density after long time storage 
 
Both, the unspecific (increased leukocyte, macrophage or lymphocyte activity (Schiffrin 
1995; Goldin 1998)) as well as the specific immune response (increased intestinal IgA re-
sponse) can be influenced by probiotics. Allergies seem to be delayed or reduced, and the 
incidence of infections was shown to be markedly decreased after newborn or premature 
infants had received the probiotic E. coli strain PZ720 (Lodinová-Zádníková 2003).  
 
A summary of some molecular mechanisms of probiotic action which underlie the benefi-
cial effects is provided by Table 1 (according to Marco 2006). 
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Table 1: Molecular mechanisms of action by which probiotics modulate human health.  
Effect Molecular mechanisms Reference 
Modulation of the 
immune response 
Inactivation of NF-κB (e.g. through proteasome inhibi-
tion or inhibition of NF-κB translocation to the nuclei) 
Æ e.g. reduction of TNFα-induced IL-8 expression 
Induction of IL-10 producing, regulatory T cells in 
vitro through the interaction of Lactobacillus strains 
with a specific dendritic cell receptor (DC-SIGN) 
Petrof 2004 
Ma 2004 
 
Smits 2005 
Strengthening of 
the intestinal barrier
Induction of heat shock proteins by VSL#3 in vitro 
and in vivo Æ stabilization of the actin cytoskeleton 
Induction of antimicrobial peptides (hBD-2) 
Petrof 2004 
 
Wehkamp 2004 
Antagonizing of  
pathogens by: 
  
Production of anti-
microbial products 
L. rhamnosus GG exerts antimicrobial activity against 
Salmonella typhimurium by secreting bactericidal 
substances + lactic acid (↓ pH) 
De Keersmaecker 
2006 
Competition for 
mucosal adhesion 
sites 
Exhibition of adhesins similar to those of pathogens 
Æ inhibit pathogen attachment (e.g. L. plantarum 
binds to mannose receptor likewise as enteropatho-
genic E. coli) 
Pretzer 2005 
 
1.3.1 Prophylactic or therapeutic application of probiotics 
Prescription of probiotics or “biotherapeutic agents” is generally considered to improve 
constitutional health or to overcome disease as an adjunct to medical therapy. In the past 
decades, several in vitro and in vivo trials have been conducted in search of more solid 
evidence of the benefits of probiotics. 
Gastrointestinal infections 
The main prerequisite for the protective effect of probiotics in the gut is the adhesion to 
and colonization of the mucosa. It is hypothesized that masking of cell wall receptors or 
direct inactivation via aggregation, suppresses the negative potential of pathogens. Bernet-
Camard et al (1997) reported that the L. acidophilus (johnsonii) strain La1 remarkably in-
hibited the adhesion and invasion of pathogens such as Salmonella, Listeria or Shigella to 
enterocytes. The reduced invasion of pathogens was thereby partially due to antimicrobial 
substances secreted by La1. Another study has reported a reduced incidence of acute diar-
rhoea and rotavirus shedding in hospitalized infants under 2 years of age (39 % control 
formula versus 10 % supplemented formula) (Saavedra 1994) receiving a formula supple-
mented with Bifidobacterium bifidum or Streptococcus thermophilus. Several other studies 
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confirm, especially in infants, that the duration and extent of diarrhoea can be cut by the 
intake of probiotics (Gaon 2003; Rosenfeldt 2002). In adults, the efficacy of probiotics is 
presented by shorter durations of traveller’s diarrhoea and other self-limited gastrointesti-
nal infections (Black 1989; Vanderhoof 2001; Marteau 2001).  
Anticancerogenic effects 
Evidence for cancer-preventing properties of pro- and prebiotics is found in studies on fae-
cal enzyme activities in animals and humans, detoxification of genotoxins in the gut in 
vitro and in vivo and suppression of carcinogen-induced preneoplastic lesions and tumours 
in laboratory animals (Goldin 1996). Some of these studies indicate that combinations of 
pro- and prebiotics ('synbiotics') are more effective. Epidemiological and intervention stud-
ies provide some, albeit limited, evidence for protective effects of products containing pro-
biotics in humans. Scientifically evident is the reduction of key enzyme activities in can-
cerogenesis as well as cell proliferation (Ballongue 1997).  
Use of probiotics in inflammatory bowel disease 
Therapy of IBD often involves induction of remission with corticosteroids and mainte-
nance therapy with a combination of aminosalicylates and immunomodulators. Patients 
treated with long-term corticosteroids may suffer from complications including growth 
failure or osteopenia. Aminosalicylates (e.g., sulfasalazine, mesalamine) are also used to 
maintain remission and have a modest effect with more than 50 % relapses after 1 year.  
 
Alternative and complementary therapies such as probiotics might induce or contribute to 
remission maintenance in IBD by modifying the bacterial environment without severe ad-
verse effects. Favourable investigations in experimental murine colitis have been con-
ducted with E. coli Nissle leading to an amelioration of disease (Schultz 2004) next to anti-
inflammatory influences on T cell proliferation and function (Sturm 2005). However, Lac-
tobacillus rhamnosus strain GG (LGG) failed to extend remission time in patients with 
CD. The time to relapse was identical between the probiotic and placebo group (Bousvaros 
2005).  
Despite the failure of most probiotics in Crohn´s disease, Saccharomyces boulardii, a non-
pathogenic yeast exerted beneficial effects in the maintenance treatment of Crohn s dis-
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ease when combined with mesalamine (Guslandi 2000). Studies on the impact of probiot-
ics on remission maintenance in ulcerative colitis and prophylaxis of pouchitis are very 
convincing. LGG was capable to prolonge the relapse-free time in UC (Zocco 2006).  
Three independent studies have found an equal efficacy for E. coli Nissle compared to 
aminosalicylates, the standard treatment for remission maintenance in ulcerative colitis 
(Kruis 1997; Rembacken 1999; Kruis 2004). The probiotic mixture VSL#3, composed of 
eight different bacterial species, is effective in primary and secondary prevention of 
pouchitis after proctocolectomy in ulcerative colitis and improved the quality-of-life scores 
of the patients (Gionchetti 2000; Gionchetti 2003; Mimura 2004). Further, VSL#3-
treatment of patients with mild to moderate UC, not responding to conventional therapy, 
resulted in a combined induction of remission/response rate of 77 % with no adverse 
events (Bibiloni 2005).  
 
1.4 Defensins – genetics, expression and regulation 
We have recently provided a possible explanation for the probiotic effect of E. coli Nissle 
as it provokes inducible human beta defensin-2 (hBD-2) expression in an intestinal epithe-
lial cell line (Wehkamp 2004). Defensins, such as hBD-2, are components of the armoury 
of endogenous antimicrobials, which are part of the innate immune system. They are 
highly conserved molecules in terms of genomics, proteomics regulation and function from 
Drosophila to higher mammals (Bevins 1996; Boman 1996, 1998; Lehrer and Ganz 1999; 
Schroeder 1999a). Defensins are small cationic peptides with a characteristic β-sheet-rich 
fold and a framework of six disulphide-linked cysteines (Fig. 2). 
 
 
 
 
 
 
 
Figure 2: β-sheet structure of the human β-defensin 2  
      (Source: http://www.phoenixpeptide.com/Catalog%20Files/BD/bc0727004011.gif) 
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Defensins can be classified into two main subfamilies, α- and β-defensins, based on their 
tertiary structure (another subfamily, the circular θ-defensins does not exist in humans but 
in rhesus macaque leukocytes (Tang 1999)). Defensins are either constitutively expressed 
(e.g., hBD-1) or inducible by bacteria or cytokines (hBD-2, -3 and -4) (Table 2).  
 
To date, six human alpha-defensins have been identified and are further subdivided into 
two groups, the human neutrophil peptides (HNPs 1-4) and the human defensins (HDs 5-
6). The human α-defensin peptides (3.5 - 4 kDa) are abundant within neutrophils and Pa-
neth cells of the small intestine (Boman 1998, Lehrer and Ganz 1999, Schroeder 1999b) 
whereas the distribution of β-defensins (4 - 6 kDa) is strictly limited to epithelial cells. 
 
Table 2: Overview of representative human antimicrobial peptides. The table shows the 
expression pattern in different cell types (adapted from Oppenheim 2003). 
Peptide Constitutive expression Induced by proinflammatory cytokines  
and endotoxin (LPS) 
α-defensins    HNP 1-4 
                        HD  5-6 
Neutrophil granules 
Paneth cell granules 
(small intestine) 
Monocytes  
CD8 T lymphocytes (CTL)  
β-defensins       HBD 1 
 
Keratinocytes  
Barrier epithelial cells  
Keratinocytes  
Monocytes and dendritic cells 
                     HBD 2-4 
 
 Barrier epithelial cells, Keratinocytes, Mast 
cells 
                     HBD 5-6 Epididymis Monocytes and dendritic cells  
 
Human β-defensins provide a first line of defence against potentially pathogenic microbes 
at the body’s mucosal frontiers (Boman 1998, Lehrer and Ganz 1999, Schroeder 1999b). 
Evaluation of the human genome suggests the existence of an additional 25 β-defensins 
that have not yet been identified (Schutte 2002). 
 
The role of β-defensins will be further considered in more detail. Single genes, clustered 
amongst the defensin locus within chromosome 8 p22-23.1 encode inactive pre-pro-
peptide forms of the β-defensin gene products (Liu 1997, 1998; Harder 1997b). They are 
subsequently processed by proteolytic factors to form mature, bioactive peptides of 28 to 
44 amino acids in length (Bals 1998, Valore 1998). In epidermal keratinocytes, human β-
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defensin 2 (hBD-2) is secreted in lamellar bodies (Oren 2003), which are lipid-containing 
vesicles that are secreted into the intercellular space and impermeabilize the skin to water. 
Apparently, these vesicles also generate the antimicrobial barrier in the epidermis. 
 
In addition to defensins, other human antimicrobial peptides are cathelicidins ((LL-
37/hCAP-18) (in neutrophil granules, barrier epithelial cells, keratinocytes, monocytes and 
T-lymphocytes), hepcidins (in blood ultrafiltrate and urine, acting as an iron-regulatory 
hormone (Kluver 2002; Krause 2003, Ganz 2006)), dermicidins (eccrine sweat glands 
(Rieg 2004; Schittek 2001)), histatins found in saliva (Oppenheim 1988; Sabatini 1989) 
and thrombocidins (or platelet microbicidal proteins) which are released upon contact with 
pathogens or stimulation with thrombin (Krijgsveld 2000; Yeaman 1999). 
 
1.4.1 Mechanisms of activity of defensins 
Defensins, or so-called arginine-rich cationic peptides, are defined by their high cathodal 
electrophoretic mobility, which influences their antimicrobial activity against gram-
negative and -positive bacteria, fungi and viruses (Table 3).  
 
Table 3: Antimicrobial spectrum of ß-defensins 
hBD-1 E. coli , Haemophilus influenzae 
hBD-2 Gram-negative bacteria, Candida albicans, H. pylori, S. typhi-
murium, Haemophilus influenzae, Pseudomonas aeruginosa, 
HIV, rhinovirus 
hBD-3 
 
Gram-negative (P. aeruginosa, E.coli, H. pylori) and gram-
positive bacteria (Streptococcus pyogenes, Staphylococcus 
aureus, MRSA, Enterococcus faecium), S. cerecisia, Cand. albi-
cans 
hBD-4 Pseudomonas aeruginosa, Staphylococcus carnosus 
 
Membranes were recognized early on as the targets for many antibacterial peptides 
(Hultmark 1980; Steiner 1982) and permeabilization of target membranes is the crucial 
step in defensin-mediated antimicrobial activity and cytotoxicity. 
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Figure 3: Staphylococcus aureus killing by defensins. Transmission electron micrographs of 
S. aureus (108 cells/ml) incubated in 10 mM phosphate buffer for 2 h (A) or treated with syn-
thetic hBD-3 (500 µg/ml) for 30 min (B) or 2 h (C and D) are shown. Bars represent 0.1 µm. 
(adapted from Harder 2001) 
 
Harder et al presented the antimicrobial activity of isolated hBD-3 (Fig. 3). When S. 
aureus was incubated with hBD-3, it showed perforations of the peripheral cell wall with 
an explosion-like liberation of the plasma membrane within 30 min. After 2 h most bacteria 
were lysed with different degrees of cellular disintegration. 
 
Artificial membranes have been used to demonstrate voltage-dependent channel formation 
by defensins (Kagan 1990). When a negative potential is applied to the membrane side 
opposite to the defensin-containing solvent, the defensins are electrophoretically driven 
into the membrane, they aggregate to form complexes based on their amphipathic struc-
ture, which results in a loss of membrane integrity, ATP production, potassium pump func-
tion, respiration and eventually cell death (Fig. 4).  
 
Necessary conditions for sufficient electrostatic forces between anionic phospholipid 
headgroups and cationic defensins are low concentrations of salts and plasma proteins, 
which would otherwise competitively inhibit the defensin antimicrobial activity (Bals 
1998; Lehrer 1988). 
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Defensin
Electric 
field
 
Figure 4: Model of antimicrobial activity of defensins. Defensins as amphipathic molecules have 
clusters of positively charged amino-acid side chains (pink) and hydrophobic amino-acid 
side chains (grey). Electrostatic attraction (by the negatively charged microbial phospholipid 
membrane) and the transmembrane bioelectric field draw the peptide molecules towards and 
into the membrane. The accumulation of the peptides leads to straining of the membrane and 
after a new arrangement to the formation of pores in the membrane (adapted from Ganz 
2003). 
 
When viruses attack cells, glycoproteins on both, the cell surface and on the virus, are 
spread apart which results in membrane fusion.  
It was recently reported that the θ-defensins retrocyclin-1 and -2 as well as hBD-3 inhib-
ited membrane fusion mediated by the viral hemagglutinin by erecting a protective barri-
cade of immobilized surface glycoproteins (Leikina 2005; Owen 2004). While this does 
not necessarily kill the virus, cell attack is stopped and the viruses can be destroyed by 
other immune responses. 
Additional activity spectrum of defensins 
It is increasingly evident that defensins do not only act as endogenous antibiotics, but dis-
play also a range of other functions, including activities that are involved in regulating 
immune responses and inflammation (e.g., interaction with Toll-like receptors, chemotactic 
effects), wound repair, and sperm function (Hiemstra 2006; Kluver 2006).  
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Activities of β-defensins include: 
• Induction of prostaglandin D2 production in mast cells (Niyonsaba 2001) 
• Degranulation of mast cells Æ histamine release (Niyonsaba 2001) 
• Chemotactic activity regarding cells expressing the receptor CCR6 (e.g., 
 immature dendritic cells and some CD8 T lymphocytes) (Yang 1999)  
• Immunoadjuvant effects in mice (Biragyn 2001):  
Enhanced antitumour adaptive immune responses 
Murine β-defensin (mBD-2) induces cytokines and chemokines 
 
Recently, Kougias et al (2005) detected neutrophil defensins and cathelicidins in high con-
centrations in atherosclerotic plaques in humans, which may imply a role as potential me-
diators of vascular disease. Preliminary results from in vitro and animal studies revealed 
that defensins are involved in lipoprotein metabolism in the vessel wall, favouring LDL 
and lipoprotein (a) accumulation and its modification in the endothelium. They also exhibit 
prothrombotic activity and inhibitory effects in angiogenesis. Cathelicidins on the other 
hand enhance endothelial proliferation and induce angiogenesis in animal models; further, 
they regulate endothelial cell apoptosis. These observations suggest an important role of 
defensins as a link between innate and adaptive immune responses.  
 
1.4.2 Association of a dysregulated defensin expression with diseases 
Recent studies describing clinical associations between diseases and defensin production 
suggest that these peptides have important and diverse functions. 
Cystic fibrosis 
The main cause of morbidity and mortality in cystic fibrosis (CF) patients is respiratory 
failure due to progressive destruction of the airways and lungs by recurrent infections and 
inflammation. In early childhood, the epithelial surfaces of the respiratory tract can be 
colonized by S. aureus and/or Hemophilus influenzae, which are eventually succeeded by 
Pseudomonas aeruginosa supporting the onset of progressive lung destruction. These 
events indicate a local defect in epithelial host defence, as the infection usually remains 
limited to the lung. Smith et al (1996) suggested that the local host defence impairment is 
caused by inhibited defensin activity through abnormally elevated salt concentrations in 
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epithelial cells, due to the defective transepithelial chloride transport. In a human bronchial 
xenograft model hBD-1 was shown to be directly affected, thus leading to the hypothesis 
by Goldman et al (1997), that increased pulmonary infections in CF might be also due in 
part to the inactivation of antimicrobial peptides. A primary defect in β-defensin produc-
tion or secretion was not found when comparing bronchoalveolarlavage fluid from CF pa-
tients and healthy subjects, supporting the view that not the quantity but the quality i.e. 
functionality of hBD-2 was affected (Singh 1998). Despite this preliminary evidence, a 
role for defensins in CF pathogenesis remains speculative.  
Psoriasis and atopic dermatitis 
The skin is frequently exposed to bacterial attacks. However, patients with psoriasis (a 
non-infectious inflammatory skin-disease) rarely suffer from skin infections. Harder et al 
(1997a) hypothesized that lesional psoriatic skin might contain antimicrobial peptides 
(AMP) which served as a “chemical shield” that resists infections. After purification of 
AMPs from psoriatic-scale extracts they discovered the presence of hBD-2, HNP 1-3, ly-
sozyme and other antimicrobial peptides (Harder 2005). Liu et al (1998) found increased 
amounts of hBD-2 mRNA in inflamed skin epidermal cells whereas keratinocytes from 
healthy skin areas did not express hBD-2. In contrast to psoriasis, patients with atopic der-
matitis had lower amounts of the AMPs LL-37 and hBD-2, and these patients were fre-
quently subject to skin infection by microorganisms such as S. aureus. This strain was able 
to colonize and infect skin from patients with atopic dermatitis but not patients with psoria-
sis or normal skin that had become inflamed from some other cause, probably due to the 
reduced production of AMPs in atopic disease (Ong 2002).  
Gastrointestinal diseases 
Increasing evidence has arisen in recent years that a dysregulated defensin expression cor-
relates with diseases of the gut. Elson (1998) hypothesized, especially for Crohn´s disease, 
a dysregulated immune response of the mucosal immune system to commensal enteric bac-
terial antigens. Human α-defensins in intestinal epithelium are exclusively expressed by 
Paneth cells in the crypts of the small intestine (Fig. 5I) (Jones 1992; Ouellette 1997), but 
can be aberrantly produced in metaplastic Paneth cells in the colon (Fig. 5E) or stomach 
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(Fig. 5H) during inflammatory bowel diseases (Cunliffe 2001; Wehkamp 2002b; Fahlgren 
2003). 
 
 
Figure 5: Expression of defensin peptide and mRNA at various sites of the GIT (Source: Wehkamp 
2005) IHC, immunohistochemistry; ISH, in situ hybridization. 
 
HBD-1 is constitutively expressed in almost all tissues in the gastrointestinal tract (Fig. 5A 
biliary tree, 6C colon, 5F stomach). In contrast, hBD-2 expression is induced by inflamma-
tion such as ulcerative colitis (Fig. 5D) or H. pylori induced gastritis (Fig. 5G) (O´Neil 
2000; Wehkamp 2003a). Furthermore, Wehkamp et al (2003b) demonstrated an impaired 
hBD-2 and hBD-3 induction in Crohn´s disease in opposite to ulcerative colitis 
Consequently, it has been hypothesized that a defect in the antimicrobial defence system of 
defensins might lie at the root of a persisting but slow bacterial invasion triggering the in-
flammatory process (Fellermann 2003).  
 
1.5 Signalling pathways involved in the innate immune response 
HBD-2 can be induced by two different activation pathways: Firstly, endogenous stimuli 
like proinflammatory cytokines (IL-1β, TNF-α, IL-22) which are mostly produced by 
macrophages and monocytes of the host. Secondly, exogenous stimuli such as E. coli 
bacteria where specific prokaryote motifs called PAMPs (pathogenic associated molecular 
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patterns) are recognized by cellular receptors. In the second case the so-called Toll-like 
receptors (TLRs), named for their homology to the drosophila toll protein, form the best-
characterized family of mammalian PAMP receptors (Takeda 2003). They recognize a 
wide array of conserved microbial products, such as lipopolysaccharide (LPS), lipoprotein, 
peptidoglycan, unmethylated CpG motifs occurring in microbial DNA or bacterial flagellin 
(Takeda 2003; Akira 2001; Athman 2004) (Fig. 6). 
 
 
Figure 6: TLR ligand diversity. TLR1 to TLR11 have been identified and characterized to date. 
TLR1, 2, 4 and 6 have lipid ligands, TLR3, 7, 8 and 9 have nucleic acid ligands and TLR5 
has a protein ligand. TLR11 recognizes uropathogenic bacteria as its ligand. The ligand for 
TLR10 is unknown. (Source: Cario 2005) 
 
These prokaryote motifs are shared by both pathogenic and commensal bacteria, giving 
rise to the affirmation that either type of bacteria might trigger innate immune responses in 
IECs. 
Certain TLR´s need adaptor proteins for proper signal transduction as in the case of TLR4 
which forms a complex with MD-2, that is necessary for surface expression and LPS-
regulated activation of TLR4 (Yang 2000). RP105 acts also as an LPS sensor in B cells 
and requires MD-2-related protein MD-1 for its surface expression (Ogata 2000; Miura 
1998).  
In addition, some TLR´s (e.g., TLR1, TLR6) act as coreceptors with other TLR´s (e.g., 
TLR2) (Ozinsky 2000). TLR´s have an intracellular domain that is homologous to the IL-1 
receptor and known as TIR (Toll/IL-1R homology). Its activation results in the recruitment 
of the adaptor protein MyD88, activation of the IRAK family, TRAF6 and of TAK-1, 
which subsequently activates NF-κB through IκB kinases and is involved in the activation 
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of the AP-1 transcription family members Jun and Fos, by way of diverse MAP kinases 
(Aderem 2000).  
The exact mechanisms by which inflammatory mediators upregulate hBD-2 have been 
intensively investigated. Cytokines and bacterial factors seem to induce hBD-2 expression 
by influencing the activities of protein kinase C (PKC), mitogen-activated protein kinases 
(MAPKs) as well as transcriptional factors e.g. the nuclear factor-κB (NF-κB) (Table 4). 
 
Table 4: Transcriptional regulation of hBD-2 gene expression and involved MAPkinases 
Cell type Involved … Not involved  Stimuli Reference 
     
Madin–Darby bovine 
kidney epithelial cells 
NF-κB  Isoleucine Fehlbaum, 2000 
MKN45 epithelial 
tissue cells (stomach 
mucosal tumor cells) 
NF-κB (p65/p65) p50/p50 
p65/p50 
H. pylori Wada, 2001 
Gingival epithelial 
cells 
p38, JNK NF-κB  Fusobacterium 
nucleatum 
Krisanaprakornkit, 
2002 
Human middle ear 
epithelial cells 
ERK1/2 MAPK  IL-1α Moon, 2002 
Airway epithelial cells  
(LC2/ad) 
NF-κB, AP-1, 
intracellular Ca2+ 
 LPS Tomita, 2002 
mononuclear phago-
cytes (RAW264.7) 
NF-κB  STAT, NF-IL-6, 
AP-1 
LPS Tsutsumii-Ishii, 
2002 
Corneal epithelial 
cells 
NF-κB, JNK, p38 ERK1/2  IL-1β  McDermott, 2003 
Alveolar epithelial 
adenocarcinoma cells  
PKC, p38, JNK, 
PI3K, NF-κB  
ERK1/2 IL-1β  Jang, 2004 
Human airway 
epithelial cells 
NF-κB  JAK IL-17 Kao, 2004 
Colonic epithelial 
cells (Caco-2) 
NF-κB, AP-1, JNK ERK1/2, p38 E. coli Nissle Wehkamp, 2004 
 
NF-κB is ubiquitously expressed and governs the expression of multiple genes encoding 
cytokines, chemokines, growth factors or some acute phase proteins. Several agents such 
as cytokines, oxidant free radicals and bacterial or viral products activate NF-κB. Inappro-
priate activation has been linked to inflammatory events associated with autoimmune ar-
thritis, asthma and AIDS. In contrast, complete and persistent inhibition of NF-κB is asso-
ciated with apoptosis, inappropriate immune cell development and delayed cell growth 
(Chen 1999).  
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In resting cells, NF-κB resides in the cytoplasm in an inactive form bound to an inhibitory 
protein known as IκB (Fig. 7). Upon cellular activation by extracellular stimuli, IκB is 
phosphorylated which induces the polyubiquitination of IкB and further degradation by the 
26S-proteasome, thereby activating NF-κB, which subsequently translocates into the nu-
cleus. NF-κB initiates early-response gene transcription by binding to decameric κB mo-
tifs, found in the promoter or enhancer regions of specific genes (Chen 1999). 
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Figure 7: NF-кB activation (adapted from Figure 1, Makarov et al., 2000) 
 
NF-κB is regarded as a genetic switch, which controls early-response gene expression; the 
synergistic interaction of NF-κB with other transcription factors such as STAT, AP-1, or 
NF-IL-6 might also be required to achieve a purposeful induction of a particular gene. Al-
though NF-κB binding sites have been identified in the promoter regions of many genes 
(including defensins) not all of them are upregulated by NF-κB in a given cell type under 
every stimulatory condition.  
 
We have recently demonstrated that hBD-2 expression stimulated by the probiotic strain E. 
coli Nissle requires NF-κB and AP-1 but one cannot eliminate the possibility that further 
transcription factors are of relevance, too (Wehkamp 2004). 
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1.6 The E. coli strain Nissle and its characteristics 
In 1916, Alfred Nissle attempted to implant non-lactic acid bacteria such as Escherichia 
coli for “causal fighting against pathological intestinal flora” (Nissle 1916). The admini-
stration of the probiotic E. coli Nissle has been reported since as an advantageous alterna-
tive treatment for remission maintenance in ulcerative colitis as this strain colonizes well 
(48 weeks after withdrawal bacterial DNA was still detectable in faecal samples) and is not 
killed by simultaneous mesalamine administration (Nguyen-Xuan 2006). Further, recent 
results state a clearly reduced duration of unspecific prolonged diarrhoea in infants and 
toddlers by administration of this strain with a treatment efficacy of higher statistical sig-
nificance than any of the preceding studies with lactobacilli (Isolauri 1991, Guandalini 
2000, Szajewska 2005). Despite the successful therapeutic applications of E. coli Nissle, 
only limited information is available about the beneficial traits contributing to the strains' 
probiotic character.  
 
The absence of defined virulence traits (i.e. alpha-hemolysin, P-, M- and S-fimbrial ad-
hesins), its non-invasiveness, the lack of invasion-associated type III protein secretion sys-
tem and the missing toxin production (enterotoxins, cytotoxins, shiga-like toxins) contrib-
ute to E. coli Nissle´s safe character. Further, this bacterium exhibits many known fitness 
factors (Fig. 8) which promote its competitiveness and effective colonization of the host 
(Lodinová-Zádníková 1997, Nguyen-Xuan 2006). It secretes the microcins M and H47 
(Patzer 2003), peptide antibiotics, that are insensitive to proteases and active against gram-
negative bacteria. E. coli Nissle attaches to the gastrointestinal epithelium by means of 
specific fimbriae (type I, F1C, curli) which bind to glycoprotein on the epithelial cell sur-
face. E. coli Nissle is able to produce a bacterial biofilm on the tissue surface by use of its 
cellulose synthesis genes, which form parts of the extracellular matrix. The biofilm might 
have influence on the signal transduction of pathogens by masking cellular receptors.  
 
In addition to its main function in providing bacterial motility, the E. coli Nissle flagellum 
plays a role for adhesion and biofilm formation on the mucosa. About 50 genes are re-
quired for flagellar synthesis and function. The flagellar apparatus consists of several dis-
tinct proteins: a system of rings embedded in the cell envelope (the basal body), a hook-
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like structure near the cell surface, and the flagellar filament. The basal body and hook 
anchor the whip-like filament to the cell surface.  
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Figure 8: Characteristics of E. coli Nissle (fitness factors) Source: Ardeypharm 
 
The availability of Fe (II) ions, an essential factor for bacterial growth, is limited in the 
mammalian host; therefore, the six iron-uptake systems (e.g., yersiniabactin, enterobactin 
or aerobactin) of E. coli Nissle contribute to its competitiveness amongst other bacteria in 
the GIT (Grozdanov 2004). E. coli Nissle has two specific small “cryptic” plasmids. These 
plasmids do not carry any genes other than those necessary for their own maintenance and 
transmission whereas plasmids generally carry genes, which increase the “fitness” of bac-
teria such as antibiotic resistance genes and support the survival of the bacterium (selection 
advantage). E. coli Nissle is serum sensitive in contrast to probiotic lactobacilli.  
 
The strain exhibits an unusual lipopolysaccharide structure due to a mutation in the wzy 
gene which encodes the O6 antigen polymerase. The absence of this polymerase leads to a 
semirough phenotype (O6-sidechain contains only one repeating unit), which is responsi-
ble for its serum sensitivity (Grozdanov 2002) and might explain its apathogenic and im-
munostimulatory characteristics. 
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3 OBJECTIVES 
The aim of the present study was, to investigate the mechanism that probiotic bacteria use to 
stimulate the chemical defence system of the human intestine. Furthermore, the missing link 
between the recognition of the bacterial ligand by its specific cell receptor and the further sig-
nalling pathway leading to the final defensin expression was a main focus of our investiga-
tions. Since E. coli Nissle (Mutaflor®) is a well-characterized probiotic agent in medicine, we 
were further interested to identify the hBD-2 inducing bacterial component of this strain.  
 
Consequently, the goal of the current work was to investigate the following: 
• Find a suitable in vitro model to study the defensin expression induced by probiotics 
• Investigate the expression and transcriptional regulation of the human β-defensin 2 
gene activated by different probiotic strains 
• Elucidate the signalling pathways by which probiotics induce hBD-2 gene expression 
in Caco-2 cells  
• Identify and isolate the unknown hBD-2 inducing factor of the probiotic strain E. coli 
Nissle  
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4 MATERIAL AND METHODS 
4.1 Material 
4.1.1 Chemicals and reagents 
Agarose Roth (Karlsruhe) 
AG126 Calbiochem (Darmstadt) 
Ampicillin Sigma (Deisenhofen) 
Bromphenolblue Merck (Darmstadt) 
Chloroform Roth (Karlsruhe) 
Complete, Mini, EDTA-free protease inhibitor cocktail 
tablets 
Roche (Mannheim) 
Coomassie brilliant blue R-250  Biorad (München) 
DEPC Roth (Karlsruhe) 
DMSO Sigma (Deisenhofen) 
EDTA Roth (Karlsruhe) 
Ethidiumbromid Sigma (Deisenhofen) 
Ethylenediamintetraaceticacid Sigma (Deisenhofen) 
Fetal calf serum Biochrom AG (Berlin) 
Gentamicin-sulfate Gibco (Karlsruhe) 
Guanidinhydrochloride Roth (Karlsruhe) 
Interleukin-1ß Sigma (Deisenhofen) 
Isopropanol Roth (Karlsruhe) 
LPS of E. coli, Serotype O111:B4 Sigma (Deisenhofen) 
Macroprep® CM Support Biorad (München) 
(NH4)2SO4 Sigma (Deisenhofen) 
SB203580 Tocris (Ellisville, MO, USA) 
Skim milk powder Fluka (Buchs, CH) 
SP600125 Tocris (Ellisville, MO, USA) 
SuperSignal® West Dura Extended Duration Sub-
strate 
Pierce (Rockford, IL, USA) 
Tris-Base Roth (Karlsruhe) 
Triton-X 100 Sigma (Deisenhofen) 
TRIzol Reagent Invitrogen (Groningen, NL) 
Tween-20 Merck (Darmstadt) 
U-73122 Calbiochem (Darmstadt) 
U-73343 Calbiochem (Darmstadt) 
X-Gal Roth (Karlsruhe) 
Xylenecyanol Merck (Darmstadt) 
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All non-listed chemicals were obtained from Sigma, Roth and Merck. Deionised water was 
used to prepare buffers and solutions. 
 
4.1.2 General material 
Product Manufacturer 
  
Combitips Eppendorf (Hamburg) 
Cryotube vials Nunc (Roskilde, Denmark) 
Dialysis tubing Servapor®             Serva (Heidelberg) 
Gel blotting paper Schleicher & Schuell (Dassel) 
Luminometer tubes Sarstedt (Nümbrecht) 
Microcuvettes Eppendorf (Hamburg) 
Multiwell plates Becton Dickinson (Heidelberg) 
Nalgene® Cryo 1 °C Freezing Container Nalge Nunc (Rochester, NY, USA) 
Neubauer Counting cell chamber Roth (Karlsruhe) 
Nitrocellulosemembrane Protran BA 85 Schleicher & Schuell (Keene, USA) 
NuPAGE® Bis-Tris SDS-PAGE  Invitrogen (Carlsbad, CA, USA) 
Tissue culture flasks 75 cm² Greiner (Frickenhausen) 
 
4.1.3 General technical tools 
Product Manufacturer 
  
Bio Photometer Eppendorf (Hamburg) 
Blotting chamber Trans-Blot® SD Semi-Dry 
Transfer Cell 
Biorad (München) 
Chemoluminescence camera CCD LAS-1000 Fuji (Tokyo ,Japan) 
Electrophoresis chamber B 1A Peqlab (Erlangen) 
Geldrying apparatus Model 583 Biorad (München) 
Heating block DB-2A Techne (Duxford, UK) 
Incubator Heraeus (Stuttgart) 
Luminometer Autolumat Plus Berthold (Bad Wildbad) 
Nitrogen tank Union carbide Messer (Griesheim) 
OptimaTM MAX-E Ultra Centrifuge Beckmann Instruments (Fullerton, USA) 
Power supply Power Pac®  Biorad (München) 
Precision balance AC 100 Mettler-Waagen GmbH (Gießen) 
Thermomixer Eppendorf (Hamburg) 
Sterile working bench Gelaire Flow Laboratories 
Thermocycler MJ Research PTC-225 Biozym (Oldenburg) 
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UV-Emissiontable and camera for gel documen-
tation 
Cybertech (Berlin) 
VictorTM 1420 multilabel counter (photometer for 
96 well plates) 
Wallac (Turku, Finland) 
Vortexer M2 Minishaker IKA (Wilmington, NC, USA) 
Waterbath HAAKE  Thermo Haake (Karlsruhe) 
XCell SureLockTM Mini-Cell Invitrogen (Groningen, NL) 
 
All other non-listed material was standard laboratory equipment. 
 
4.1.4 Standards 
Product Manufacturer 
  
100 bp DNA-Ladder                                  Gibco (Karlsruhe) 
1 kb DNA-Ladder Gibco (Karlsruhe) 
DNA Molecular Weight Marker VI Roche (Mannheim) 
DNA Molecular Weight Marker VIII          Roche (Mannheim) 
Multi Mark Multi-Coloured Standard (Protein) Invitrogen (Groningen, NL) 
Sea Blue® Plus 2 Pre-Stained Standard (Pro-
tein) 
Invitrogen (Groningen, NL) 
 
4.1.5 Protein, enzymes and peptides 
Product Manufacturer 
  
AMV Reverse Transcriptase Promega (Mannheim) 
BSA Sigma (Deisenhofen) 
HBD-2 peptide Peptide Institute (Osaka, Japan) 
MEM Non essential amino acids Gibco (Karlsruhe) 
Proteinase K Qiagen (Hilden) 
Restrictionenzymes Hind III, Sph I, Xho I, Xba I New England BioLabs (Beverly, MA, USA) 
Trypsin-EDTA Gibco (Karlsruhe) 
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4.1.6 Antibodies 
Primary and secondary antibodies 
 
Antibody Type Source  Dilution 
    
Anti H1 E. coli Polyclonal 
rabbit 
Statens Serum Institute, Copenhagen, 
Denmark 
1:100 
Anti H7 E. coli  polyclonal 
rabbit 
T.K. Korhonen (General Microbiology, Fac-
ulty of Biosciences, FIN-00014 University of 
Helsinki, Finland) 
1:5000 
HRP-conjugated 
IgG 
Anti-rabbit Calbiochem 1:5000 
HRP-conjugated 
IgG  
goat anti-
rabbit  
Dianova, Hamburg 1:5000 
 
4.1.7 Buffers and solutions for SDS-PAGE and Western blot analysis 
Product Ingredients Manufacturer 
   
Loading buffer 4 x NuPage LDS Sample Buffer  Invitrogen 
Running buffer NuPAGE® MES SDS Running Buffer  Invitrogen 
Fixing solution: Methanol 
Acetic acid 
H2O 
50 % (v/v) 
10 % (v/v) 
40 % (v/v) 
 
Coomassie blue 
staining solution: 
50 %  Methanol 
Coomassie brilliant blue R-250  
Acetic acid 
H2O 
50 % (v/v) 
0.05 % 
(v/v) 
10 % (v/v) 
40 % (v/v) 
 
 
Transferbuffer    Invitrogen 
10 x TBS 
(Washbuffer) 
Tris-Base       
NaCl               
KCl                 
pH 7.4 
0.25 M 
1.4 M   
27 mM           
 
 
 
TBST: 10 x TBS   
Tween-20 
10 % (v/v) 
0.1 % (v/v) 
 
 
Blocking buffer TBST 
Skim Milk powder 
 
5 % (w/v) 
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4.1.8 Reagents and solutions for isolation and analysis of RNA 
Name Ingredients Concentration 
  
10 x Formaldehyde-
buffer 
MOPS 
Sodiumacetate 
EDTA 
pH 7.2 adjusted with acetic 
acid 
200 mM 
50 mM 
10 mM 
6 x RNA-Loadingbuffer Bromphenolblue 
Xylenecyanol 
Saccharose 
DEPC- H2O 
0.25 % (w/v) 
0.25 % (w/v) 
40 % (w/v) 
49.5 % (v/v) 
50 x TAE-Buffer Tris 
Eisessig 
EDTA 
2 M 
5.1 % 
50 mM 
Ethidiumbromidestock Ethidiumbromide 
RNAse-free water 
0.5 µg/µl 
 
4.1.9 Plasmids and oligonucleotides 
Plasmids for transfection experiments or used as PCR standard are listed in Table 5. 
 
Table 5: Plasmids  
Plasmids Origin 
 
pNF-κB-luc  Clontech BD Biosciences (San Diego, USA) 
pAP-1-luc  Clontech BD Biosciences (San Diego, USA) 
pGL3-Basic Vector: 
hBD-2-luc 
hBD-2 NF-κB-mut1+2-luc  
hBD-2 NF-κB-mut1+2+3-luc 
hBD-2 AP-1-mut-luc 
hBD-2 AP-1+NF-κB-mut-luc 
Dr. Jürgen Harder, Clinic of Dermatology, Kiel 
 
phRG-TK (Renilla) Promega (Madison, USA) 
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Oligonucleotides (Table 6) were ordered from MWG Biotech (Ebersberg) in HPSF-
purified form, solubilized with the respective amount of nuclease-free water and stored at -
20 °C. For the PCR the oligo´s were adjusted to a concentration of 0.5 µM and stored 
short-term between succeeding PCR runs at 4-8 °C. 
 
Table 6: Oligonucleotides used in the present study 
Name mM MgCl2 bp product Sequence (5´→ 3´) 
 
hBD-2 3 172 
for ATCAGCCATGAGGGTCTTGT 
rev  GAGACCACAGGTGCCAATTT 
GAPDH 3 360 
for  CCAGCCGAGCCACATCGCTC 
rev  ATGAGCCCCAGCCTTCTCCAT 
TLR-1 3 105 
for CAGTGTCTGGTACACTCATGGT 
rev  TTTCAAAAACCGTGTCTGTTAAGAGA 
TLR-2 4.5 67 
for GGCCAGCAAATTACCTGTGTG 
rev AGGCGGACATCCTGAACCT 
TLR-3 6 82 
for CCTGGTTTGTTAATTGGATTAACGA 
rev TGAGGTGGAGTGTTGCAAAGG 
TLR-4 3 135 
for TGCTTCTTGCTGGCTGCATA 
rev ATACGTCGGTCGTTCTTCGT 
TLR-5 3 77 
for TGCCTTGAAGCCTTCAGTTATG 
rev CCAACCACCACCATGATGAG 
TLR-6 5.5 88 
for GAAGAAGAACAACCCTTTAGGATAGC 
rev AGGCAAACAAAATGGAAGCTT 
TLR-7 5.5 72 
for TTACCTGGATGGAAACCAGCTA 
rev TCAAGGCTGAGAAGCTGTAAGCTA 
TLR-9 3 151 
for GGACCTCTGGTACTGCTTCCA 
rev AAGCTCGTTGTACACCCAGTCT 
TLR-10 2 102 
for CTCCCTGGATGCAGTCATTT 
rev AACTTCCTGGCAGCTCTGAA 
MD-1 2 101 
for TAGCTCTCATGTCTCAAGGCTCAT 
rev ATCTGCTCTCCTTTCCTTCTTCC 
MD-2  2 99 
for ATTCCAAGGAGAGATTTAAAGCAATT 
rev CAGATCCTCGGCAAATAACTTCTT 
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Name mM MgCl2 bp product Sequence (5´→ 3´) 
MyD88 4 100 
for TGAGGGAGCCTAACCATGTC 
rev TTGGTCCTTTCCAGAGTTTG 
RP105  4 142 
for CTGGACTGCACTTGCTCGAATAT 
rev CACAGGAAAGCTTTGACATCAGATAG 
CD14 2 90 
for CGCTCCGAGATGCATGTG 
rev TTGGCTGGCAGTCCTTTAGG 
 
Table 7: PCR-programs for the different PCR targets 
Oligonucleotides Annealing/Melting temperature 
 
hBD-2  62 °C/95 °C 
GAPDH 66° - 60 °C/95 °C 
TLR-1, -2, -3, -5, -6, -7 
MyD88, RP105, CD14, MD1, MD2 
68° - 60 °C/96 °C 
TLR-4, -9 and -10 68° - 64 °C/95 °C 
 
4.1.10 Commercial Kits 
Product Manufacturer 
 
Dual Luciferase® Reporter Assay System Promega (Madison, WI, USA) 
Human IL-8 ELISA Kit II BD Biosciences (San Diego, USA) 
LightCycler-FastStart DNA Master SYBR Green I 
mix 
Roche Diagnostics GmbH (Mannheim) 
MTT Cell Proliferation Assay ATCC (Manassas, VA, USA) 
Quantum PrepTM Plasmid Midiprep Kit Bio-Rad (Hercules, CA, USA) 
QIAprep Spin Miniprep Kit Qiagen (Hilden) 
Reverse Transcription System Promega (Madison, WI, USA) 
VenorGeM® mycoplasma detection kit Minerva Biolabs GmbH 
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4.2 Methods 
 
Cell culture experiments 
 
 
  
 
 
4.2.1 Cell cultivation 
Cellline No. Medium Source 
 
Caco-2  ACC 169 DMEM  DSMZ 
T84 ATCC CCL-248 Ham’s F12/DMEM ATCC 
SW480 ACC 313 RPMI 1640 Dr. Oelschlaeger, Würzburg 
SW620 ATCC CCL-227 DMEM ATCC 
 
For studying the expression of the antimicrobial peptide hBD-2, we used four different 
human colonic adenocarcinoma cell lines. It is known that Caco-2 cells express the antim-
icrobial peptide α1-antitrypsin (Perlmutter 1989; Molmenti 1993). This cell line has also 
been a useful tool to study functions of mature enterocytes. SW620 cells display high me-
tastatic potential compared to SW480 cells with low metastatic potential. 
 
Transfection for 24 h 
Stimulation 4.5 h 
Stimulation 6 h 
RNA-isolation 
cDNA-synthesis Reporter gene assay 
(Firefly and Renilla  
Luciferase expression) 
 
 
RT-PCR 
(mRNA expression) 
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4.2.1.1 Cell culture media 
Cell line Media 
 
Caco-2  
SW620 
DMEM 25 mM HEPES 
+ 10 % fetal calf serum  (FCS) 
+ 50 µg /ml gentamicin 
+ 1 % non essential amino acids 
T84 DMEM/Ham´s F12   1:1 
+ 15 mM HEPES 
+ 14 mM NaHCO3 
+ 5 % fetal calf serum 
+ 100 U/ml penicillin 
+ 100 µg/ml streptomycin 
SW480 RPMI 
+ 10 % fetal calf serum 
+ 2 mM glutamine 
+ 14 mM NaHCO3 
 + 100 U/ml penicillin 
+ 100 µg/ml streptomycin 
 
Cultivation was carried out in a humidified atmosphere at 37 °C and 5% CO2/95 % O2. 
Cells were subcultured weekly and split with a density of 1:10 or 1:20 according to need. 
Cells were used between passages 5 and 35. To detect any contamination with my-
coplasma, which could be disguised by the use of antibiotics we used the VenorGeM® 
mycoplasma detection kit. This test is based on a fast and very sensitive detection of my-
coplasma-DNA in biological samples via PCR. Cells were prepared for this test by cultiva-
tion for 2 weeks without any antibiotics and further prepared as mentioned in the supplier’s 
protocol. 
 
4.2.1.2 Treatment of cells with stimulants 
For stimulation experiments, cells were seeded at a density of 2.8 x 105 cells/4 cm² in 12-
well culture plates (Becton Dickinson GmbH). Cells grown to ~70 % confluence on culture 
wells were incubated with serum- and antibiotic-free medium for at least 12 h to eliminate 
serum-induced IL-8 release or hBD-2 expression and prevent any influence of antibiotics 
on the immune response. Cells were stimulated at 37 °C for the specified times.  
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4.2.1.3 Cell differentiation  
We investigated in Caco-2 cells whether the expression of hBD-2 is influenced by the de-
gree of differentiation. This cell line, differentiating spontaneously in culture (Rousset 
1985) was grown for 1, 2, 3, 6, 9 or 12 days to achieve different stages of differentiation 
(Table 8) before stimulation with 5 ng/ml IL-1β for 6h after an overnight incubation in 
FCS-/AB-free medium. The culture medium was changed every 2 days during the growth 
phase. The expression of hBD-2 and GAPDH was determined via RT-PCR. 
 
Table 8: Differentiation grade (Source: Bernet-Camard 1996) 
Days of growth Characteristics 
 
Up to 5 days (2-3 days in our experiment) 
Up to 7 days (4 days          “                     ) 
Up to 10 days (8 days        “                     ) 
Up to 15 days (12 days      “                     ) 
Confluence, undifferentiated state 
Postconfluence, differentiation starts 
Differentiation develops 
Differentiation complete 
 
4.2.2 Preparation of human PBMC´s 
Since leukocytes contain a number of Toll-like receptors they served as a positive control 
in comparison to the TLR expression in the epithelial cell lines. PBMC´s were isolated 
from whole blood by Ficoll-density-gradient-centrifugation. After centrifugation at 400 x g 
for 25 min (without brake) the interphase was carefully collected and diluted 1:1 with PBS. 
Cells were centrifuged for 5 min at 400 x g and 4 °C. Supernatant was removed, PBMC-
pellets were dissolved in PBS with protease inhibitor cocktail (Complete Mini, EDTA-
free) and stored at -20 °C. RNA was isolated from the cells, reverse transcribed into cDNA 
and the expression of TLR´s and adaptor molecules determined. 
 
4.2.3 TLR spectrum 
Caco-2, T84, SW480 and SW620 cells were cultured until confluency and RNA was iso-
lated. For the detection of the different TLR´s and adaptor proteins PCR programs (Table 
7) were established. MgCl2 concentration was tested from 2, 3, 4 to 5 mM for each primer 
pair (Table 6) and annealing temperatures adjusted to measure several TLR´s in one run. 
We further determined, whether TLR expression could be induced by stimulation of Caco-
2 cells with IL-1β (5ng/ml) for 6 h. The PCR data was evaluated qualitatively by ethidium 
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bromide staining of the PCR products run on a 2 % gel for 1 h. Further, the melting curves 
were analysed to test for specificity of the oligonucleotides.  
 
4.2.4 Bacteria cultivation 
Bacteria strains used in the present study are shown in Table 9. For cultivation 10 ml of 
sterilized Trypticase soy broth (TSB) (Table 10) was inoculated with 1 pearl of bacteria 
from the frozen stock and grown overnight with shaking at 200 rpm at 37 °C. To obtain 
bacteria in a linear growth phase, 100 µl of the bacterial suspension was added to 10 ml of 
fresh TSB medium and grown with constant shaking for 5 h. Preliminary studies by 
Wehkamp et al (2004) showed that living bacteria induced hBD-2. However, using viable 
bacteria would have the disadvantage of overgrowth in the cell culture wells; hence, we 
decided to heat-kill the bacteria to maintain stable culture conditions and bacterial concen-
trations. Heat-inactivation was carried out in a water bath at 65 °C for 1h. Bacterial culture 
supernatants were collected by centrifugation at 4000 × g for 10 min. The bacteria pellet 
was washed with PBS, and after another centrifugation step adjusted to 3 × 108 cells/ml. 
Since this cell number corresponds to an optical density (OD) of 0.3, we controlled the 
concentration of bacteria by absorption measurements with a spectrophotometer at 595 nm. 
The supernatant was diluted by the same dilution factor as the bacteria in FCS- and antibi-
otic-free cell culture medium. The bacteria pellet and supernatant were stored at -20 °C 
until use.  
 
Lactobacilli and Pediococcus are facultative anaerobes (or facultative aerobes) defined as 
organisms that can switch between aerobic and anaerobic types of metabolism. Under an-
aerobic conditions, they grow by fermentation or anaerobic respiration, but in the presence 
of O2 they switch to aerobic respiration. Lactobacilli, Pediococcus and Leuconostoc were 
cultivated according to De Man, Rogosa and Sharpe in MRS Broth (Table 10) for 18-24 h 
in a CO2 enriched atmosphere in an anaerobic jar. The anaerobic environment was gener-
ated by placing an AnaeroGenTM sachet (OXOID, Basingstoke, Hampshire, England) in 
the jar, which resulted in a rapid absorption of oxygen and simultaneous generation of 
CO2. In the stationary phase, 300-500 µl of bacteria were transferred into fresh media and 
grown for another 5-7 h depending on the individual growth rate. The bacteria were heat-
inactivated, washed and adjusted to the same cell concentration as mentioned above. Since 
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the light absorption varies with the geometry of the dispersing particle size of the microor-
ganisms, different OD values are obtained between cocci and rods. Therefore, we had to 
calculate which OD refers to the bacterial cell number of 3 x 108/ml for each lactobacilli 
strain. Bacteria were diluted and 10 µl were added onto a Fuchs-Rosenthal counting cham-
ber (depth: 0.2 mm; size: 0.0625 mm2). The obtained cell number was multiplied with the 
factors 64 and 312.5.  
 
Table 9: Bacteria strains. EcN∆ strains are E. coli Nissle strains with deletions of the traits 
listed below. 
Strain Serotypec Characteristics/Isolatetype Source 
 
E. coli Nissle 1917 (DSM 
6601) 
O6:K5:H1 Apathogen, pharmaceutical strain ACS 
EcNΔHPI 
EcNΔfim 
EcNΔfoc 
EcNΔfimΔfoc 
EcNΔcsgBA 
EcNΔbcs 
EcNΔmcmDAB 
EcNΔK5 
EcNΔc 
EcNΔfliA 
EcNΔfliC 
EcNΔflgE 
EcNΔfliCpDB2 
EcNΔflgEpDB3 
E. coli JM109 ATCC 
53323 
CFT073∆hly–CFT073 WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orough:H48 
O6:K2:H1 
Yersiniabactin-gene cluster  
type 1 pili (=fimbriae) 
F1C pili (=fimbriae) 
type 1 pili + F1C pili 
curli (= fimbriae) 
cellulose-synthesis-gene cluster 
microcin 
capsule 5–gene cluster  
plasmid 
sigma factor of flagella genes 
flagellin filament protein 
hook 
complementant of fliC 
complementant of flgE 
Control strain 
Uropathogenic E. coli  with de-
leted haemolysin gene 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
E. coli PZ720 O83:K24:H31 Probiotic strain ACS 
E. coli PZ830 O4:H- Fecal isolate ACS* 
E. coli ATCC 25922   Clinical isolate, Reference strain KaE 
E. coli  K12 (DSM498)  Reference strain DSMZ 
E. coli  K12 (DH5α)  Reference strain DSMZ 
Salmonella enterica se-
rovar Enteritidis 
 Intestinal isolate 2 
One Shot® Top 10F´ E. 
coli 
 Competent cells for transforma-
tion 
Invitrogen 
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Strain Strain desig-
nation 
Isolatetype Source 
L. acidophilus  PZ 1030  
(DSM 20079) 
Reference strain ACS (DSMZ) 
L. acidophilus  PZ 1041
  
Paidoflor® ACS 
L. acidophilus PZ 1129 Industrial probiotic strain ACS 
L. acidophilus PZ 1130  
(JCM 1132) 
Reference strain ACS (GR) 
L. acidophilus PZ 1138 Industrial probiotic strain  
L. gasseri PZ1144  
(DSM 20243) 
Reference strain ACS (DSMZ) 
L. gasseri PZ 1160 Intestinal isolate ACS 
L. fermentum PZ 1162
  
Intestinal isolate ACS 
L. plantarum (2592) LMG P-20606 Growing rye 24a, BCCM 
Leuconostoc  
mesenteroides (77:1) 
LMG P-20607 Growing rye 24a, BCCM 
Pediococcus  
pentosaceus (16:1) 
LMG P-20608 Intestinal isolate 24a, BCCM 
L. paracasei subsp.  
paracasei (F19) 
LMG P-17806 Growing rye 24b, BCCM 
VSL#3  Industrial probiotic mixture  3 
 
ACS, Ardeypharm Collection of Strains, Herdecke *, strain obtained from A.M. Snelling and P. Hawkey, 
Department of Microbiology, University of Leeds, United Kingdom 
GR, strain collection of G. Reuter (strain deposited by Mitusoka at the Japanese Collection of Microorgan-
isms) 
BCCM, Belgian Coordinated Collection of Microorganisms 
DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig 
KaE, Collection of strains, Klinik am Eichert, Göppingen  
1 Collection of strains University of Würzburg  
2 Patient isolate from the Robert Bosch Hospital, Stuttgart 
3 sigma-tau Arzneimittel GmbH, Düsseldorf 
c Serotyping of strains was performed by S. Aleksic, Institute of Hygiene, Hamburg. H-, no H antigen (cells 
nonmotile). 
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For testing dose dependency, bacteria were used at concentrations between 106 and 109 
bacteria/ml. Bacteria supernatant was used undiluted or was adjusted with DMEM (--+) to 
the following dilutions 1:2, 1:4, 1:10, 1:100 and 1:1000. 
 
Table 10: Bacteria culture media and solutions 
Bacteria Media  Source 
 
TOP 10F´ competent E. coli Luria Bertani (LB) Sigma 
TOP 10F´ competent E. coli SOC medium Invitrogen 
TOP 10F´ competent E. coli X-Gal: 
40 mg/ml in dimethylformamide 
Roth 
Lactobacilli (anaerobic 
growth) 
MRS Broth:  
51 g MRS/L distilled water  
0.1 % Tween 80 
Fluka (Buchs, CH) 
 
Fluka 
E. coli, Salmonella TSB:  pH 7.3 
1.7 %   Peptone from casein 
0.3 %   Peptone from soy 
0.25 % Glucose 
0.5 %   NaCl 
0.25 % Dipotassiumhydrogen- 
            phosphate          
 
Roth 
Roth 
 
 
4.2.5 Molecularbiological methods 
4.2.5.1 RNA isolation and cDNA synthesis 
At the end of the stimulation experiments, cells were washed twice with phosphate-
buffered saline (PBS), lysed with 500 µl TRIzol reagent/4 cm² well surface for 5 minutes, 
transferred to a tube and frozen at -80 °C. RNA was isolated according to the supplier’s 
protocol. The RNA pellet was dissolved according to its size in 15-25 µl DEPC-H2O. RNA 
quality and quantity were determined by gel electrophoresis and photometry. Subsequently 
1 µg of total RNA was reverse transcribed into cDNA with oligo (dT) primers and 15 U/µg 
AMV Reverse Transcriptase according to the manufacturer’s protocol (Promega).  
 
4.2.5.2 Real-time RT-PCR 
Real-time reverse transcription PCR (RT-PCR) analyses were performed in a fluorescence 
temperature cycler (LightCycler; Roche) according to the manufacturer's instructions. This 
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technique continuously monitors the cycle-by-cycle accumulation of the fluorescently la-
belled PCR product. As a template, cDNA corresponding to 10 ng of RNA in a 10 µl reac-
tion mixture containing the specific concentration of MgCl2, 0.5 µM of each primer and 1 
× LightCycler-FastStart DNA Master SYBR Green I mix was used.  
 
Samples were loaded into capillary tubes and placed in the fluorescence thermocycler 
(LightCycler). Initial denaturation at 95 °C for 10 min was followed by 45 cycles, each 
cycle consisting of 95 °C for 15 s, the primer-specific annealing temperature (Table 7) for 
5 s and 72 °C for 15 sec. At the end of each run melting curve profiles were obtained by 
cooling the sample to 65 °C for 15 s and then heating slowly at 0.20 °C/s up to 95 °C with 
continuous measurement of fluorescence to confirm amplification of specific transcripts. 
Cycle-to-cycle fluorescence emission readings were monitored and analyzed using 
LightCycler software (Roche Diagnostics GmbH).  
 
The specificity of the amplification products was verified by subjecting the amplification 
products to electrophoresis at 100 V for 1 h on a 2 % agarose gel containing ethidium bro-
mide. All quantifications were normalized to the housekeeping gene GAPDH. Relative 
expression is given as a ratio between target gene expression and GAPDH gene expres-
sion.  
 
4.2.5.3 Calculation of the mRNA copy number 
For the quantitative evaluation of the hBD-2 gene expression by Real Time PCR the cali-
bration with DNA-solutions of known copy number was necessary. Therefore, the concen-
tration of isolated plasmid-DNA (QIAprep Spin Miniprep Kit) was measured at 260 nm in 
the photometer and adjusted to 1 ng/µl and the copy number in the plasmid-solution was 
calculated using the following formula: 
 
 
A, plasmid concentration calculated by 260 nm absorbance (g/ml); B, basepairs of plasmid vector; C, base-
pairs of insert; D, average molecular weight of desoxy-nucleosidemonophosphates (NMP´s): 330 g/mol 
 
 
Plasmid copy number (copies/ml) =
A x 6.023 x 1023
(B + C) x D x 2
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Molecular weight of the vector: 
Basepairs (bp) of vector pCR-Blunt II-TOPO: 3519
bp of insert hBD-2: 172
bp of vector with insert: 3691
bp of double-strand vector + insert: 7382
Molecular weight of double strand vector + insert: 330 g/mol x 7382  
= 2436060 g/mol
 
Amount of substance [mol] of the stock solution of hBD-2: 
Spectrophotometric measurement of hBD-2 DNA-concentration: 1 ng/ml
1 mol double strand vector + insert: 2436060 g
1 g double strand vector + insert: 4.104989 x 10-7 mol
1 ng double strand vector + insert: 4.104989 x 10-16 mol
 
Conversion of the amount of substance to the amount of particles [= copy number]: 
1 Mol = 6.023 x 10²³ particles [Avogadro constant] 
4.104989 x 10-16 mol = 2.472435 x 108 copies/ng  
 
The stock solution of the clone hBD-2 contains 1 ng/µl DNA, which matches ~ 2.47 x 108 
copies/µl. For the creation of standard curves, dilution series were made starting from 1 ng 
plasmid DNA (101 to107 copies). In each run, two samples of the standard curve were in-
cluded as a control. To avoid variations in DNA-concentrations by repeated freezing and 
thawing of the standard samples, 5-10 µl aliquots for all dilutions were prepared, thawed 
once and then stored at 4 °C. 
 
4.2.5.4 Chemical transformation and isolation of plasmid-DNA  
For the transformation of competent E. coli with plasmids for transfection or the utilization 
as standards for the PCR, 1 µl plasmid was added to 1 vial of competent E. coli Top 10 F´ 
cells and incubated for 15-30 min on ice. Then cells were heat-shocked for exactly 30 sec 
in a water bath at 42 °C and immediately placed on ice for 2 minutes. 250 µl of SOC me-
dium was added and tubes shaken for 1 h at 37 °C. 25 µl of the transformation reaction 
was plated on LB agar plates containing 50 µg/ml ampicillin and 40 µg/ml X-Gal in di-
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methylformamide. After incubation overnight at 37 °C, recombinants were identified by 
blue/white colour screening. White colonies were picked and grown for about 14 h in 40 
ml (for transfection) or 5 ml (for PCR) LB medium (containing ampicillin). Plasmid DNA 
was purified according to the manufacturer’s protocol (Quantum PrepTM Plasmid Midiprep 
(transfection) or QIAprep Spin Miniprep Kit (PCR)) and eluted in Tris-Cl or DNAse free 
water. DNA concentration was determined photometrically at a wavelength of 260 nm 
(extinction maximum of nucleic acids). Contamination was identified by a low ratio of the 
260 nm/280 nm value; pure samples should have a ratio between 1.8 and 2.0. 
 
4.2.5.5 Restriction enzyme analysis and agarose gel electrophoresis 
0.5 µg of plasmid-DNA was digested by restriction enzymes as described by the manufac-
turer (New England BioLabs). For hBD-2 pGL3 Hind III + Xho I was used, for NF-κB 
Hind III + Xba I and for AP-1 Hind III + Sph I. After at least 2 h of incubation at 37 °C the 
digested DNA was analyzed in 0.8 % agarose gels prepared in 1 x TAE buffer and contain-
ing 5 % ethidium bromide. Prior to electrophoresis, DNA was mixed with six fold concen-
trated loading buffer. Electrophoresis was performed in 1 x TAE buffer at a constant volt-
age of 90 V for 1.5 h. The DNA in the agarose gels was visualized using ultraviolet light 
(302 nm) and photographed subsequently with a videodocumentation system (Cybertech, 
Berlin). 
 
4.2.5.6 Luciferase reporter gene assay 
To assess hBD-2 promoter activity, Caco-2 cells were seeded into 12-well culture plates 
(2.8 × 105 cells/ml/well) and transfected upon 70 % confluency. The luciferase reporter 
constructs for hBD-2-2338-luc, NF-κB-mut1+2-luc, NF-κB-mut1+2+3-luc, AP-1-mut-luc 
and AP-1+NF-κB-mut-luc were kindly provided by Dr. Jürgen Harder (University of Kiel) 
and were constructed as described by Wehkamp et al (2004). Cells were transfected with 
0.5 µg hBD-2 reporter plasmid and 0.05 µg of an internal control Renilla luciferase expres-
sion plasmid (phRG-TK) by using 1 µl of FuGENE 6 transfection reagent (Roche Diag-
nostics GmbH, Mannheim, Germany) according to the manufacturer’s protocol. 24 h after 
transfection, cells were treated for 4.5 h with various stimuli.  
For signalling pathway studies mitogen-activated protein (MAP) kinase inhibitors AG126, 
SB203580 and SP600125 were used and resuspended in dimethyl sulfoxide (DMSO). 
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Cells were pre-treated with the specific ERK ½, p38 and JNK inhibitors 1 h prior to stimu-
lation. At the end of the experiment, cells were washed with PBS and 250 µl of passive 
lysis buffer (Promega) was dispensed into each well. The culture plate was placed on a 
rocking platform for 15 min and the lysate transferred to a tube for the storage at -80 °C. 
Before the measurement of luciferase activities, the lysate samples were cleared by cen-
trifugation for 1 min at 10 000 rpm in a refrigerated microcentrifuge. Firefly luciferase 
activity from the hBD-2-pGL3, NF-κB or AP-1 reporter vector and Renilla luciferase ac-
tivity were analyzed as described for the Dual-Luciferase® Reporter Assay System Kit 
using a luminometer. Promoter activity was determined as a ratio between Firefly and 
Renilla luciferase activities. Means were normalized to basal unstimulated luminescence of 
controls, set at 1. In MAPkinase studies or bacteria mutant studies the bacterial supernatant 
was set at 100 and the inhibited or mutant stimuli were adjusted to this value in %.  
 
4.2.5.7 Cell viability test 
To confirm that pharmacological inhibitors were not toxic for Caco-2 cells, cell viability 
was assessed using the MTT Cell Proliferation Assay, which measures the mitochondrial 
function. Briefly, metabolically active cells reduce the yellow tetrazolium MTT to the pur-
ple formazan product by dehydrogenase enzymes. Caco-2 cells were seeded into a 96 well 
plate with a density of 0.35 x 105 cells/well. 24 h later cells were incubated in the presence 
of MAP kinase inhibitors, DMSO or anti-inflammatory drugs for 6-12 h. Then media was 
removed and DMEM (--+) was added to the cells. After 24 h of incubation 10 µl of MTT 
(10 mg/ml) was added to each well for a 2 h period. After the formation of formazan crys-
tals 90 µl lysisbuffer/well was added and cells were lysed overnight at room temperature 
under soft shaking packed into aluminium foil to protect them from light. The absorbance 
was measured at 550 nm using the photometer Victor. It has been shown previously that 
viable cell numbers correlate with optical density, as determined by the MTT assay (Twen-
tyman 1987).  
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4.2.6 Methods to determine the hBD-2 inducing factor from E. coli Nissle 
Cell wall component
Yes ? No ?
LPS ? DNA ?Secreted or shed factor
Protease resistance
Heat stability
Mutation of bacterial molecules
Pos. ?
Purification and analysis of bacterial factor
Cell culture
experiment
Induction of hBD-2 expression ?  
 
4.2.6.1 LPS from E. coli Nissle  
LPS from E. coli serotype O111:B4 (Sigma-Aldrich) and highly purified LPS isolated 
from E. coli Nissle kindly provided by Dr. Zähringer (Research Center Borstel) were di-
luted in FCS-/ and AB-free DMEM and adjusted to different concentrations (0.1, 0.5, 1 
and 5 µg/ml) and Caco-2 cells were incubated for 6 h with these endotoxins. 
 
4.2.6.2 DNA isolation from bacteria 
For isolation of bacterial DNA, Protocol D on p. 53 of the QIAamp® DNA Mini kit manual 
(Qiagen) and continued as described for the DNA isolation from tissue, was used. To in-
crease the DNA concentration in the obtained DNA yield, the DNA was precipitated with 
ethanol, frozen at -80 °C, centrifuged and the pellet dissolved in Tris-Cl buffer. Synthetic 
oligodeoxynucleotides (ODN) with immunostimulatory CpG-motifs were commercially 
synthesized by MWG Biotech (Ebersberg) in a phosphothioate protected form. The phos-
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phothioate modification replaces 1 of the 2 nonbridging oxygens of the internucleotide 
phosphate with sulphur, thus preventing nuclease activity and extending greatly the half-
life (Crooke 1995). The sequence of ODN-2006 GC (negative control) differs from ODN-
2006 (positive control) by the methylated cytosines at positions 2, 5, 13 and 21 (see be-
low). With hBD-2 transfected Caco-2 cells were stimulated with E. coli Nissle DNA, 
ODN-2006 and ODN-2006 GC and hBD-2 promoter activation was monitored after 4.5 h.  
 
Name Sequence (5´→ 3´)  
 
ODN-2006 
ODN-2006 GC 
5´-TCGTCGTTTTGTCGTTTTGTCGTT-3´ 
5´-TGCTGCTTTTGTGCTTTTGTGCTT-3´ 
 
Reference: Bauer 2001 
 
4.2.6.3 Heat stability test 
To characterise further the hBD-2 inducing factor, E. coli Nissle supernatant was heated 
for 20 min at 100 °C. TSB was treated accordingly as a negative control. Non-boiled, 
boiled bacteria supernatant and TSB were added to Caco-2 cells for 6 h to observe whether 
the heat treatment had any deteriorating effect on hBD-2 inducing capacity.  
 
4.2.6.4 Protein digestion in bacterial culture supernatant 
Bacterial supernatant diluted to the appropriate concentration in DMEM was subjected to 
10 µl proteinase K (>600 mAU/ml)/100 µl supernatant or an aliquot of TSB/DMEM as a 
control for effects of proteinase K for 1 h at 56 °C. To terminate further proteolysis the 
suspension was heated for 20 min at 100 °C. Protein content was determined in treated and 
non-treated bacterial supernatant, which was then placed onto Caco-2 cells for 6 h. 
 
4.2.6.5 Construction of bacteria mutants 
The deletion of specific bacterial genes from E. coli Nissle was carried out by Artur Alten-
hoefer (University of Würzburg). The isogenic mutant strains ΔHPI, Δfim, Δfoc, ΔfimΔfoc, 
ΔcsgBA, Δbcs, ΔmcmDAB, ΔK5, Δc, ΔfliA, ΔfliC and ΔflgE (see Table 8) were constructed 
according to a method previously described (Datsenko 2000). The single gene clusters 
were replaced by a cat antibiotic resistance cassette, which was part of a PCR product, 
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generated with plasmid pKD3 as the template and the respective primer pair; here illus-
trated for the flagellin mutants:  
p1 (5´-AAGATAGCGGCTTAATGGCCGTGTGTAGGCTGGAGCTGCTT-3‘) and p2 
(5´-CGTTCATCCCTGGGGGCTATCCCATATGAATATCCTCCTTAGTTCCTA-3‘) for 
ΔfliA, p3 (5´-GGCAATTTGGCGTTGCCGTCAGGTGTAGGCTGGAGCTGCTT-3‘) and 
p4 (5´-ACGGCGATTGAGCCGACGGGTGCATATGAATATCCTCCTTAGTTCCTA-
3‘) for ΔfliC or p5 (5´-ACGCTGGATCTCGGCACTTACGGTGTAGGCTGGAGCTG-
CTT-3‘) and p6 (5´-TGTTGATTCAGCGTCTGGCTGGCATATGAATATCCTCCTTAG-
TTCCTA-3‘) for ΔflgE.  
 
The construction of the microcin-negative (ΔmcmDAB) and the fim- and foc-negative mu-
tants was described by Altenhoefer et al (2004). EcNΔc (Nissle 1917 cured of both plas-
mids) was generated according to the German Patent Nr. 103 28 669. From the resulting 
chloramphenicol resistant E. coli Nissle 1917 derivate the cat cassette was not deleted after 
transformation for better selection of the derivates.  
 
The flagellin mutant E. coli Nissle 1917 ΔfliC and ΔflgE strains were complemented with a 
PCR-product of the lacking gene cloned into the pGEM®-T Easy Vector (Promega, Madi-
son, USA), corresponding complementants were labelled ΔfliCpDB2 and ΔflgEpDB3. The 
primers used for PCR corresponded to those for the deletion method in the underlined se-
quences. All mutant and complemented strains were tested for their ability to induce hBD-
2 expression either regarding promoter activation or mRNA expression as described above. 
Swarm Plate Assay 
To evaluate the effect of the deleted flagellin genes on bacterial motility, swarm plate as-
says were performed by Artur Altenhoefer (University of Würzburg). Swarm agar (0.3 %), 
containing 10 g NaCl, 5 g yeast extract, 10 g peptone and 3 g agar, was used to evaluate 
the motility of E. coli Nissle wild type, ΔfliC, ΔflgE, ΔfliA and complemented ΔfliCpDB2 
and ΔflgEpDB3 strains. Small wells were punched out in semisolid LB agar plates, loaded 
with 5 µl of each strain and incubated for 10 h at 37 °C.  
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Western blot of whole bacteria  
Heat killed bacterial samples from overnight cultures of E. coli Nissle wild type, ΔfliC, 
ΔflgE, ΔfliA and complemented ΔfliCpDB2 and ΔflgEpDB3 were used to analyse flagellin 
expression by the Western blot technique, which was kindly performed by Artur Alten-
höfer (University of Würzburg). Briefly, the resultant sample was separated in a Bio-Rad 
Modular Mini Electrophoresis System (Hercules, CA, USA) on a 12.5% polyacrylamide 
gel and then transferred to a 0.2 µm nitrocellulose membrane (Bio-Rad, München). After 
blocking of unspecific binding sites the blot was incubated overnight at 4 °C with an anti-
H7 E. coli rabbit polyclonal antibody diluted 1:5000 in blocking buffer under gentle agita-
tion. Following several washing steps with TBS, the blot was incubated for 1h with horse-
radish peroxidase (HRP)-conjugated anti-rabbit Ig (Calbiochem) diluted 1:5000 in block-
ing buffer. HRP was revealed with ECL light detection reagents (Amersham Biosciences, 
Buckinghamshire, UK) and exposed to film for 60 s (Kodak, Rochester, N.Y., USA).  
 
4.2.6.6 Purification of flagellin 
Flagellin from diverse bacterial strains were isolated as previously described (Ogushi 
2001). Briefly, 1 liter of TSB was inoculated with 10 ml of the bacteria and cultured for 16 
h at 37 °C, pelleted by centrifugation (4400 x g, 30 min, 4 °C) and resuspended in 20 ml of 
PBS. The suspension was adjusted to pH 2 with 1 M HCl and maintained at that pH with 
constant stirring at room temperature for 30 min. After centrifugation (100 000 x g, 4 °C, 1 
h) the pH of the supernatant, containing soluble monomeric flagellin, was adjusted to 7.2 
with 1 M NaOH. Solid (NH4)2SO4 was added slowly with constant stirring to obtain 65 % 
saturation. After an overnight incubation at 4 °C, the precipitate was pelleted by centrifu-
gation (15000 x g, 4 °C, 15 min). The precipitate was dissolved in 1-3 ml of distilled water 
and transferred to a dialyse tubing (MWCO 12.000 – 14.000, pore diameter ~ 25 Å) for 
concentration and desalting of the protein solution.  
For dialysis, the tubing was placed in a vessel with 1-3 liter of distilled water. Under con-
stant stirring, the solution was dialysed for 16 h at 4 °C with three water changes. To re-
move heat labile proteins the dialysate was heated at 65 °C for 15 min, placed on ice and 
centrifuged (100 000 x g, 4 °C, 1 h). 0.7 M solid (NH4)2SO4 was added to the supernatant, 
which contained depolymerised flagellin. After incubation overnight at 4 °C, polymerized 
flagellin was collected by centrifugation (100 000 x g, 4 °C, 1h) and dissolved in PBS.  
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The concentration of the isolated protein was determined using the Bradford assay (Biorad 
Laboratories, Hercules, CA, USA) with bovine serum albumine as a standard. The molecu-
lar size of the flagellin was identified by mass spectrometry performed by Dr. Harder 
(University of Kiel). The samples were diluted 1:10 in 50 % acetonitrile containing 0.02 % 
formic acid and analyzed by electrospray mass spectrometry (ESI-MS) in the positive ioni-
zation mode with a quadrupol-orthogonal-accelerating-time-of-flight-mass spectrometer 
(QTOF-II-hybrid-mass-spectrometer (Micromass, Manchester, U.K.)). The spectra were 
evaluated using the program MassLynx 3.5. (Micromass). 
SDS-PAGE of isolated flagellin 
To verify the purity of the flagellin, 4x NuPage LDS Sample buffer was added to the iso-
lated protein and heated for 10 min at 70 °C. Prestained marker and samples were pipetted 
into the wells of a 4-12 % NuPAGE® Bis-Tris gel and run for 1½ h at 100 Volt. After elec-
trophoresis, the separated fractions were treated with fixing solution for 30 min, stained for 
protein with Coomassie brilliant blue, washed with 10 % acetic acid and scanned.  
Western blot of flagellin isolates 
For further immunologic characterization the protein gel was transferred to a 0.45 µm ni-
trocellulose membrane in a blotting chamber and the protein blotted for 40 min at 1 
mA/cm² gel size on to a 0.45 µm nitrocellulose membrane (Schleicher & Schuell, Keene, 
USA) (Towbin 1979). To block free binding sites, membranes were incubated with 5 % 
skimmed milk powder in TBST for 1h. E. coli H1-antiserum (Statens Serum Institute, Co-
penhagen, Denmark) which served as primary antibody was diluted in TBST and added to 
the membrane. Following 1.5 h of incubation, strips were washed five times for 5 min each 
and incubated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit IgG 
(Dianova, Hamburg, Germany), diluted 1:5000 in TBST. After five washes with TBST, the 
membrane was incubated for 5 min in SuperSignal® West Dura Extended Duration Sub-
strate (Pierce, Rockford, IL, USA). Developing bands were detected with a chemolumines-
cence camera CCD LAS-1000 (Fuji) and analysis was performed with the software AIDA 
2.1 (Raytest, Straubenhardt, Germany). 
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4.2.7 IL-8 ELISA 
At the end of the cell culture experiments supernatants were collected and stored at -80 °C. 
IL-8 secretion in response to IL-1ß and E. coli Nissle supernatant was measured in cell 
culture supernatants from Caco-2, T84, SW480 and SW620 cells by enzyme-linked immu-
nosorbant assay (OptEIA Human IL-8 ELISA Kit II, BD Biosciences, San Diego, CA) 
according to the supplier’s protocol. Supernatants were diluted 1:10 or 1:50 for determina-
tion of IL-8. 
 
4.2.8 HBD-2 purification from cell culture supernatant for hBD-2 ELISA 
To determine the secretion of hBD-2 peptide by Caco-2 cells upon stimulation with probi-
otic bacteria, cell culture supernatants were collected at the end of the experiment, 1% 
BSA was added as a carrier and samples were stored at -20 °C. Cationic proteins were ex-
tracted overnight at 4 °C under constant gentle agitation with a weak cation exchange ma-
trix (Macroprep® CM Support beads), added at a 1:40 ratio of matrix to cell culture super-
natant including protease inhibitor cocktail (PIC) (PMSF 10 µM, Pepstatin 10 µg/ml, Leu-
peptin 10 µg/ml).  
Subsequently the beads were washed with ammonium acetate for 10 min, the supernatant 
discarded and the absorbed cations were eluted twice with 5 % acetic acid (Porter 1998). 
The eluate was collected, lyophilised under vacuum and resuspended in 0.01 % acetic acid 
(+PIC). The presence of hBD-2 peptide in the solution was finally determined by ELISA 
by Dr. Jürgen Harder as described by Wehkamp et al (2004). 
 
4.3 Statistical evaluation 
The statistical evaluation was performed with Microsoft Excel and the programs SigmaPlot 
8.0 or GraphPadInstat (Version 3.1, GraphPad Software, San Diego, CA, USA). To test for 
normality the Kolmogorov-Smirnov test was used. The data was considered as normally 
distributed when the P value was > 0.1 (10%-niveau) according to Dallal and Wilkinson’s 
approximation to Lilliefor´s method (1986). When data failed to follow a Gaussian distri-
bution, nonparametric ANOVA was performed using Kruskal-Wallis or Mann-Whitney 
Test. Means were regarded as significantly different if the null hypothesis was rejected 
with a probability of error of 5 % (p < 0.05). 
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5 RESULTS 
5.1 Expression studies in colonic epithelial cells 
5.1.1 Differential human beta defensin-2 and IL-8 expression 
In order to identify the most suitable model for studying the hBD-2 inducing effect of E. 
coli Nissle 1917, various intestinal epithelial cell lines (Caco-2, T84, SW480 and SW620 
cells) were stimulated with IL-1β and E. coli Nissle 1917 culture supernatant (Table 11). 
The positive control IL-1β induced a strong increase of hBD-2 mRNA expression in Caco-
2 cells. This increase was ~10 fold less pronounced in T84 cells. SW480 and SW620 cells 
lacked to express hBD-2 after incubation with IL-1β. 
 
Table 11: Differences of hBD-2 and IL-8 expression in intestinal epithelial cells. Relative 
HBD-2 mRNA expression in IECs after 6 h stimulation with IL-1β or E. coli Nissle su-
pernatant (sn) was measured by RT-PCR. The data represent the means ± the SD of 
three independent experiments performed in duplicate. 
Cell line Treatment hBD-2 mRNA expression IL-8 protein expression 
 
Caco-2 Unst. 
IL-1ß 
EcN sn 
0 
584.53 ± 200.86 
52.06 ± 15.06 
39.5 ± 6.35 
5510.18 ± 3730.27 
2852.38 ± 1145.3 
T84 Unst. 
IL-1ß 
EcN sn 
0 
48.38 ± 32.32 
28.63 ± 38.22 
295.1 ± 34.08 
336 ± 334.92 
981.68 ± 852.66 
SW480 Unst. 
IL-1ß 
EcN sn 
0 
0 
21.01 ± 8.4 
10.65 ± 2.28 
32.5 ± 2.12 
6379.2 ± 76.65 
SW620 Unst. 
IL-1ß 
EcN sn 
0 
0 
13.84 ± 12.04 
122.5 ± 14.85 
141 ± 18.38 
4441.86 ± 873.23 
 
A similar expression pattern was found after incubation with E. coli Nissle supernatant. 
The highest amount of hBD-2 mRNA was expressed by Caco-2 cells, half as much by T84, 
followed by SW480 cells. SW620 cells expressed only a small amount of hBD-2 after 
treatment with the bacterial supernatant (sn). Bacterial invasion or proinflammatory cyto-
kines induce in colonic epithelial cells the secretion of the cytokine IL-8 (Eckmann 1993a). 
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As hBD-2 expression was determined to be NF-κB-dependent (Wehkamp 2004; Tsutsumi-
Ishii 2002) the transcriptional regulation of IL-8 and hBD-2 gene expression might act in 
concert. We therefore determined the expression of the pro-inflammatory cytokine IL-8 to 
demonstrate that differences in hBD-2 expression between Caco-2, T84, SW480 and 
SW620 cells are not caused by an experimental artefact. Both stimulants, IL-1β and E. coli 
Nissle supernatant, induced the secretion of IL-8 by Caco-2 cells to a high extent as shown 
in Table 11. In SW480 and SW620 cells, only the bacterial supernatant evoked a strong 
expression of IL-8, which was absent following stimulation with IL-1β. In T84 cells, EcN 
supernatant induced IL-8 only weakly and IL-1β lacked any inducing effect.  
 
5.1.2 Toll-like receptors 
Toll-like receptors recognise microbial products during infection and initiate signalling 
pathways that culminate in the increased expression of immune and inflammatory genes. 
To identify potential receptors involved in E. coli Nissle signalling, we used real-time PCR 
to examine the qualitative expression of mRNAs encoding all known TLR´s and several 
adaptor proteins (e.g., CD14, MD-1, MD-2, MyD88, RP105) involved in TLR functions.  
 
 
   TLR5     TLR6     TLR7             TLR9                   CD14       RP105       MD2              MD1 
 
 
 
 
 
M1                                                    M1                      M1                                                         M1 
       TLR1              TLR10            TLR4                     TLR2               TLR3                       MyD88 
 
 
 
 
 
M2                                                                                 M1                                                         M1                  
Figure 9: TLR expression pattern in Caco-2 (1st band), T84 (2nd band), SW480 (3rd band) and 
SW620 (4th band) cells. TLR expression was assessed by real-time PCR. M1 = Mol. Weight 
Marker VIII (Roche), M2 = 100 bp DNA Ladder (Gibco) 
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The four cell lines expressed all TLR´s including their adaptor proteins (chaperones) (Fig. 
9). Peripheral blood mononuclear cells (PBMC) were used as a positive control. We inves-
tigated, whether TLR expression in Caco-2 cells was influenced by stimulation with IL-1β 
(Fig. 10). All TLR´s were expressed with similar strength whether unstimulated or stimu-
lated, suggesting a constitutive mRNA expression. Only MD-1 and -2 displayed an in-
crease after IL-1β treatment. 
 
     TLR 1        TLR2      TLR3        TLR4     TLR5        TLR6       TLR7       TLR9 
               
 
 
 
                       
M1  –  +         –  +          –  +         –  + 
       
 
 
 
 
M1  –  +         –  +         –  +         –  + 
     TLR10       MyD88       RP105       CD14     MD1     MD2 
             
 
 
 
 
M1   –  +         –  +         –  +         –  +  
 
 
 
 
 
M1  –  +       –  +  
Figure 10: TLR expression basal and IL-1β stimulated in Caco-2 cells. Caco-2 cells were stimu-
lated with IL-1β (5ng/ml) for 6 h. Stimulated and nonstimulated treatment is indicated with 
(+) or (-) respectively. M1 = Mol. Weight Marker VIII (Roche) 
 
5.2 Time- and dose-dependent hBD-2 mRNA expression 
To optimize experimental conditions Caco-2 cells were stimulated with increased concen-
trations or for different times with IL-1β bacteria pellet or supernatant to establish a dose-
response or time-dependent effect on hBD-2 expression. 
5.2.1 Induction by IL-1β 
According to previous studies, Interleukin-1 can serve as a positive control for the induc-
tion of hBD-2 (O´Neil 1999). Caco-2 cells were stimulated with 5 ng/ml IL-1β for 3 h, 6 h, 
12 h and 24 h and hBD-2 expression was measured by real-time PCR. hBD-2 mRNA ex-
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pression induced by IL-1β followed a time-dependent pattern which increased from 3 h 
(195.7 ± 49.2) to 6 h (273.6 ± 92.9) of incubation, peaked at 12 h (420.8 ± 32.9) and de-
creased after 24 h (245.4 ± 111.3). IL-8 expression was determined from the cell culture 
supernatant and was determined to accumulate from 3 h to 12 h with no further increase 
after 24 h of stimulation with 5 ng/ml IL-1β (IL-8 secretion (pg/ml) after incubation for 3 
h: 5320.9; 6 h: 8708.4; 12 h: 11397.3; 24 h: 12295.2).  
 
For dose-dependence experiments, Caco-2 cells were stimulated for 6 h with increasing 
concentrations of IL-1β. The induction of hBD-2 mRNA expression by IL-1β was dose-
dependent as seen in Table 12 and was maximal when 5 ng/ml IL-1β were applied with a 
decrease at the highest IL-1β concentration used. 
 
Table 12: Dose-dependent hBD-2 expression in Caco-2 cells by IL-1β stimulation. After 6 h 
of stimulation with ascending concentrations of IL-1β cells were lysed with TRIzol, RNA 
was isolated and reverse-transcribed and hBD-2 expression determined via RT-PCR. 
The data represent the means ± the SD of two independent experiments. 
IL-1β concentration (ng/ml) hBD-2 copies/10 ng mRNA 
 
0 
0.1 
1 
5 
10 
  1.01 ± 1.44 
   9.8 ± 2.08 
  227.2 ± 76.68 
325.32 ± 3.6 
242.66 ± 21.12 
 
5.2.2 Expression of hBD-2 by Caco-2 cells as a function of cell differentiation 
We determined that stimulation of Caco-2 cells with IL-1β resulted in a diminished hBD-2 
expression when the treatment followed more than 2 days after seeding (Fig. 11). At that 
time, cells had reached full confluency. After 3 days of growth until the 12th day, IL-1β 
induced hBD-2 expression remained stable with 400 copies/10 ng mRNA. There was a 4 
fold higher increase of the hBD-2 copy number when cells had grown to ~ 70 % conflu-
ency at the time of stimulation. According to these results, our experiments were carried 
out in the subconfluent state when cells had grown for < 2 days. 
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Figure 11: HBD-2 expression with time of cultivation. Cells were cultured for 1, 2, 3, 6, 9 and 12 
days before stimulation with 5 ng/ml IL-1ß for 6 h. The data represent the means of two 
independent experiments ± the SD. 
 
5.2.3 HBD-2 induction by different probiotic strains  
Previous data have suggested that probiotic bacteria enhance the barrier function of the gut. 
We investigated, whether they could exert this barrier stabilizing effect also by the induc-
tion of hBD-2. For all tested probiotic strains, the hBD-2 induction followed a time-
dependent pattern. The maximum of hBD-2 expression for all strains was determined at 6 
h, decreased remarkably at 12 h and reached basal levels after 24 h of incubation (Fig. 12). 
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Figure 12: Time-course of lactobacilli induced hBD-2 expression. Caco-2 cells were treated with 
six different bacterial strains for 3, 6, 12 and 24 h. The data are means ± the SD of at least 
three independent experiments. 
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Thus, we defined 6 h of incubation as the optimal time for further experiments regarding 
hBD-2 mRNA expression. 
The highest induction of hBD-2 was elicited by the probiotic cocktail VSL#3, followed 
with half as much activation by L. fermentum and Pediococcus pentosaceus. L. acidophilus 
and L. paracasei had only weak capacities to induce hBD-2.  
 
In a dose-dependence experiment, we tested the optimal dose at which the probiotic strains 
induced the highest amount of hBD-2 (Fig. 13).  
At a concentration of 1 x 106 bacteria cells/ml no hBD-2 induction was detectable. Except 
for VSL#3, no other bacteria had an inducing effect at the concentration of 1 x 107 
cells/ml. Pediococcus, L. fermentum and VSL#3 induced clearly hBD-2 mRNA expression 
at a concentration of 1 x 108 cells/ml, which was further enhanced at the highest bacteria 
cell number used. L. acidophilus induced only with 1 x 109 cells/ml hBD-2. L. paracasei 
had only weak capacity to influence hBD-2 expression in Caco-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Dose-dependent stimulation of hBD-2 expression in Caco-2 cells by lactobacilli. Cells 
were stimulated for 6 h with 106, 107, 108 and 109 bacteria cells/ml and hBD-2 expression 
was determined by RT-PCR. The data represent the means ± the SD of three independent 
experiments. 
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We tested nine different probiotic strains to clarify whether the induction of hBD-2 is a 
general feature of probiotics (Fig. 14). Amongst these strains, four were mixed to a cock-
tail for the investigation of any cumulative effects. Lactobacillus fermentum and Pediococ-
cus pentosaceus stimulated the expression of hBD-2 similarly strong as E. coli Nissle.  
 
The incubation of Caco-2 cells with L. plantarum, L. paracasei and L. acidophilus PZ 
1129 did also activate hBD-2 expression but much less pronounced than with L. fermentum 
or Pediococcus. There was no difference between E. coli K12, L .gasseri, L. acidophilus 
PZ 1030 and Leuconostoc, which induced only very low levels of hBD-2. The cocktail of 
the four strains shown in Fig. 14 induced distinctly hBD-2 but this effect seemed not to be 
cumulative compared to the different strains added individually.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: HBD-2 gene expression after stimulation with various lactobacilli. Caco-2 cells were 
incubated for 6 h with equal amounts of bacteria. Data are set in relation to E. coli Nissle 
(set as 100 %). *bacteria which are part of the cocktail. L. ac., L. acidophilus; L. ferm., 
L. fermentum  
 
These data indicate that other probiotic strains besides E. coli Nissle increase significantly 
hBD-2 gene expression but with limitation to a few strains.  
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Additionally, the probiotic-stimulated secretion of the functionally relevant hBD-2 peptide 
could be detected in the cell culture supernatant (Fig. 15).  
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Figure 15: Detection of hBD-2 peptide in culture supernatants from Caco-2 cells stimulated 
with probiotics. Caco-2 cells were incubated for 24 h with equal amounts of bacteria. 
Secreted hBD-2 peptide was concentrated and detected by ELISA.  
 
5.2.4 Induction of hBD-2 by culture supernatant of E. coli Nissle 
Caco-2 cells were stimulated for 1.5, 3, 6, 12 and 24 h with E. coli Nissle supernatant (di-
luted 1:2). Relative HBD-2 expression increased from 1.5 h (6.3 ± 0.1) to 6 h (8.02 ± 0.96) 
remained stable at 12 h (8.04 ± 2.79) and decreased remarkably after 24 h (0.36 ± 0.16) of 
incubation.  
 
IL-8 secreted into the cell culture supernatant was determined via ELISA. IL-8 protein 
(pg/ml) was expressed in a time-dependent manner, increasing highly from 1.5 h (109 ± 
9.94) to 3 h (1487 ± 125.39) and further accumulating after 6 h (2583.1 ± 1294.94) until 12 
h (3083.1 ± 255.58) of incubation reaching a plateau at 24 h (3224.7 ± 63.9). HBD-2 ex-
pression by E. coli Nissle supernatant was dose-dependent (Fig. 16). 
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Figure 16: Dose-dependency of bacteria supernatant mediated hBD-2 and IL-8 expression. 
Caco-2 cells were stimulated for 6 h with EcN and E. coli K12 supernatant diluted in AB-
/FCS-free DMEM. RNA was isolated and hBD-2 analyzed via RT-PCR. IL-8 secreted 
into the cell culture supernatant was determined via ELISA.  
 
The highest concentration of the supernatant (dilution 1:2) induced 4.7 fold as much hBD-
2 as the dilution 1:4. E. coli K12 was 8.5 fold weaker in inducing hBD-2 than E. coli 
Nissle. Since the smallest dilution of supernatant (1:2) might induce cell stress during the 
incubation time caused by a lack of nutrients, we decided to continue our experiments with 
supernatant diluted 1:4. 
 
In accordance with our observations of hBD-2 induction, IL-8 was expressed by Caco-2 
cells in a dose-dependent manner after E. coli Nissle supernatant treatment and decreasing 
gradually with reduced concentrations of the bacterial supernatant (Fig. 16). 
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5.2.4.1 HBD-2 induction by bacterial supernatant is stronger than by the pellet 
From previous studies we know, that bacterial cell wall components of E. coli Nissle are 
recognized by epithelial cells and induce hBD-2 (Wehkamp 2004). However, it remained 
unknown, whether a secreted or shed factor present in the culture supernatant of this bacte-
rium, could also activate the expression of the human beta-defensin 2.  
In reporter gene studies, we compared the hBD-2 inducing activity of bacterial cells (= 
crude pellet) and the corresponding bacterial culture supernatant (Fig. 17). Bacteria super-
natants exposed a markedly stronger hBD-2 promoter activating capacity than bacterial 
pellets of the strains tested. 
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Figure 17: Effect of crude bacterial pellet versus supernatant on hBD-2 reporter gene activity.  
Transfection of Caco-2 cells with an hBD-2 promoter construct (2338 bp) for 24 h was fol-
lowed by incubation for 4.5 h with 5 ng of IL-1β or bacterial preparations/ml. The probi-
otic fecal E. coli isolates Nissle (EcN), PZ720, and E. coli PZ830 were adjusted to a den-
sity of 3 × 108 bacteria/ml and tested either as crude bacterial pellets (p) or corresponding 
supernatants (sn) in the same amount of volume. hBD-2 promoter activation was deter-
mined as a ratio between firefly and Renilla luciferase activities. The data represent the 
median with minimum and maximum values of three to five experiments performed in 
triplicate. The median was normalized to the basal luminescence of unstimulated controls, 
set at 1. IL-1β served as positive stimulatory control (left column). A statistical comparison 
between the crude pellet and the supernatant was performed by using the Mann-Whitney 
test. * (p < 0.05), ** (p < 0.01). 
 
We also compared the hBD-2 inducing effect of pellets and supernatants of the strains L. 
fermentum, Pediococcus and L. acidophilus PZ 1129. However, these strains did not exert 
relevant differences in hBD-2 expression after stimulation with either pellet or supernatant 
p   sn p   sn p   sn 
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(2.2 fold (L. fermentum) or 1.3 fold (L. acidophilus) higher induction than with the pellet) 
except for Pediococcus (sn: 7 fold more than the pellet).  
These results suggest an immunostimulatory role for a secreted or shed factor from some 
bacterial strains but not for probiotics in general. 
 
5.3 Transcriptional regulation and signalling pathways of hBD-2 gene expression 
induced by probiotics 
5.3.1 Role of the transcription factors NF-κB and AP-1 
NF-κB and AP-1 play both a role for E. coli Nissle mediated hBD-2 gene transcription 
(Wehkamp 2004). We investigated whether the unknown factor in the bacterial supernatant 
induces hBD-2 transcription in the same way as the pellet.  
 
First, we investigated whether a NF-κB reporter gene, which is an artificial construct con-
taining several tandemly repeated NF-κB binding sites would be activated by bacterial 
stimulation after transfection into Caco-2 cells. Incubation with E. coli Nissle supernatant 
enhanced luciferase activity 5.1 fold compared to unstimulated control, with the pellet 1.4 
fold (n=3). The difference between bacterial pellet and supernatant stimulated promoter 
activation was statistically significant (p < 0.05). A similar activation profile was found for 
E. coli PZ720 (pellet: 1.2 fold, supernatant: 4.3 fold).  
In contrast, an AP-1 reporter gene was not activated by any of the stimulants indicating 
that activation of the transcription factor AP-1 alone might not be sufficient for luciferase 
expression induced by the bacteria. 
 
The importance of NF-κB and AP-1 binding sites in the promoter region of hBD-2 was 
analyzed by transfecting Caco-2 cells with three mutant hBD-2 promoter constructs en-
compassing the 5´-untranslated region upstream of the start of gene transcription (2338 
bp). Binding sites for the two 5´-upstream NF-κB sites (pos. –205 to –186 and –596 to –
572) and AP-1 (pos. –127 to –121) were mutated separately or together (Fig. 18). Maximal 
activity was observed with the complete promoter encompassing all known NF-κB and 
AP-1 sites (Fig. 19). Sequential loss of transcription factor binding sites within the hBD-2 
promoter resulted in a stepwise decrease in activation upon IL-1β, as well as pellet (EcN) 
and supernatant (EcNsn) treatment. 
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Figure 18: hBD-2 promoter constructs used to investigate the role of NF-κB and AP-1 binding 
sites. (Source: Wehkamp 2004) Symbols represent positions of putative transcription 
factor binding sites: open ovals: NF-κB sites (-186/-205; -572/-596); grey boxes: AP-1 
site (-121/-127) 
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Figure 19: Contribution of NF-κB and AP-1 binding sites to E. coli Nissle mediated hBD-2 
promoter activation. Various mutant promoter constructs were tested for their ability to 
respond to IL-1β, as well as E. coli Nissle culture supernatant (EcNsn) or crude bacterial 
pellet (EcN), in luciferase reporter gene assays as outlined in Fig. 17. NF-κB (positions 
–205 to –186 and –596 to –572) and AP-1 (positions –127 to –121) were mutated sepa-
rately (hBD-2mut N1+2 or hBD-2mut AP-1) or in combination (hBD-2mut N1+2+AP-
1). The data represent the median with minimum and maximum values of duplicate 
samples of three to four experiments. Statistical evaluation was performed by using 
Kruskal-Wallis analysis with post hoc Dunn´s test. * (p < 0.05), ** (p < 0.01).  
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More precisely, mutation of the two NF-κB binding sites reduced promoter activation by 
E. coli Nissle pellet from 7 fold to 1.8 fold, by the supernatant from 41.3 fold to 1.5 fold. 
In addition, the IL-1β mediated activation was almost completely blocked (from 255.6 to 
3.6). In summary, the deletion of the –205 to –186 and –596 to –572 sites resulted in the 
complete loss of stimuli responsiveness. Further, we determined whether a third NF-κB 
binding site (-2187) on the promoter is also relevant for transcriptional regulation. Deletion 
of the third and most distant NF-κB binding site resulted in no further loss of the basal 
transcription activity. Thus, it does not appear to be functionally relevant for hBD-2 tran-
scription. Mutation of the AP-1 site alone decreased hBD-2 promoter activation by the 
supernatant by 30 %. This suggests a limited role for AP-1, as it cannot induce promoter 
activation without activated NF-κB binding sites in its neighbourhood. After the mutation 
of AP-1 and the two NF-κB sites, promoter activation by any of the stimulants was com-
pletely abolished. Although NF-κB alone contributed greatly to the hBD-2 promoter acti-
vation, hBD-2 gene expression seemed to depend on both transcription factors.  
Whether the transcription factors NF-κB and AP-1 are also both essential for the expres-
sion of the human β-defensin-2 induced by other probiotics was further clarified (Fig. 20).  
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Figure 20: Relevance of the NF-κB and AP-1 binding sites for hBD-2 promoter activation by the 
strains L. fermentum, Pediococcus and L.acidophilus PZ 1129. Transfected cells were 
stimulated for 4.5 h with IL-1β or 3 x 108 cells/ml and Firefly and Renilla expression was  
determined. Data represent the median with minimum and maximum values of duplicate 
samples of three to four experiments. Statistical evaluation was performed by Kruskal-
Wallis analysis with posthoc Dunn´s test, ** (p < 0.01). 
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First, we investigated the effect of the deletion of the two NF-κB binding sequences closest 
to the transcription start. Activation of the promoter by L. fermentum was reduced by 64 %, 
by Pediococcus 44 % and by L. acidophilus PZ 1129 it was completely abolished. The 
deletion of the binding site for the transcription factor AP-1 diminished the promoter acti-
vation by L. fermentum, Pediococcus and L. acidophilus by 65 %, 50 % or 43 % respec-
tively.  
This suggests that AP-1 might be more important for hBD-2 transcription initiated by L. 
fermentum and L. acidophilus and Pediococcus than by E. coli Nissle. Mutation of all tran-
scriptionfactor binding sites completely abolished any promoter activation. 
 
5.3.2 Role of MAP kinases in probiotic cell signalling 
Streptococci, Staphylococci and S. 
enteritidis have been reported to 
increase hBD-2 production by 
epithelial cells by activating one or 
more MAP kinase signalling pathways 
(Chung 2004; Ogushi 2004). To de-
termine if those pathways are 
activated by the hBD-2 inducing 
factor in E. coli Nissle supernatant, we 
inhibited three main MAP kinase 
pathways with specific inhibitors: p38 
mitogen activated kinase (p38 MAPK), c-Jun amino-terminal kinases (JNK kinase), and 
the extracellular signal-regulated kinases (ERK½). Blocking of ERK½ by AG126 (AG) 
and JNK by SP600125 (SP) resulted in almost complete abrogation of E. coli Nissle super-
natant- mediated hBD-2 promoter activation. Inhibition of p38 MAP kinase by SB203580 
(SB) had the slightest effect (50 % (at 10 µM SB) or 75 % (at 50 µM SB) reduction of 
promoter activation respectively) (Fig. 21). For all experiments, IL-1β stimulation was 
used as positive control for hBD-2 promoter activation.  
The results indicate an important role for ERK½ and JNK and a limited role for p38 in the 
signalling pathway of the bacterial supernatant of E. coli Nissle.  
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Figure 21: Effects of MAP kinase inhibition on E. coli Nissle supernatant mediated hBD-2 pro-
moter activity. The hBD-2 promoter construct was transfected into Caco-2 cells. Specific 
MAP kinase inhibitors (diluted in DMSO) at the indicated concentrations were added 1 h 
prior to 4.5 h stimulation with bacterial supernatant, or the corresponding supernatant in-
cluding 0.5 % DMSO. The data are expressed as a percentage of the control response 
(EcNsn with DMSO 0.5 %) and represent the median with minimum and maximum values 
of duplicate determinations of three experiments. Each inhibitor was compared to the 
DMSO control by Kruskal-Wallis analysis and post hoc testing. * (p < 0.05), ** (p < 0.01). 
 
Focussing on hBD-2 promoter activation induced by NF-κB binding other MAP kinases 
might be involved than by AP-1.  
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Figure 22:  EcNsn induced MAPkinase signalling after deletion of the AP-1 binding site. Caco-2 
cells were transfected with an hBD-2mut AP-1 plasmid and pretreated for 1h with the spe-
cific MAP kinase inhibitors before stimulation with EcNsn. The data represent the median 
with minimum and maximum values of duplicate determinations of three experiments.  
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After deletion of the AP-1 binding site, treatment with the ERK½ inhibitor AG and the 
JNK inhibitor SP, but not with the p38 inhibitor SB resulted in a distinct decrease of 
luciferase activity (Fig. 22).  
MAP kinase involvement in the signal transduction of two other probiotic strains was also 
determined (Fig. 23). Inhibition of ERK ½ reduced hBD-2 promoter activation by L. fer-
mentum and Pediococcus by 55 %. Inhibition of p38 MAP kinase resulted in 20 % or 25 % 
decreased promoter activation through L. fermentum or Pediococcus respectively. Normal 
luciferase activation by Pediococcus was inhibited by 2/3 when incubated with the JNK 
inhibitor. Thus, JNK certainly plays a role for the signalling pathway of L. fermentum and 
Pediococcus, ERK½ is also included but p38 seems to be less important. 
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Figure 23: Signaltransduction of L. fermentum and Pediococcus mediated hBD-2 promoter acti-
vation. Caco-2 cells were transfected with a wildtype hBD-2 (-2338) promoter construct 
and stimulated with L. fermentum (dark grey) or Pediococcus (light grey) for 4.5 h after 
pretreatment with the MAP kinase inhibitors. The data represent the median with mini-
mum and maximum values of duplicate determinations of three experiments. 
 
To ensure, that the applied inhibitor concentrations dissolved in DMSO had no cytotoxic or 
growth inhibiting effect we performed the MTT cytotoxicity assay as described in Meth-
ods. The concentrations of the MAPkinase inhibitors AG126, SB203580 and SP600125 
used for the cell culture experiments caused no significant changes of cell viability. This is 
indicated by the equivalent mitochondrial activities between untreated cells (DMEM) and 
inhibitor-treated or DMSO treated cells (Fig. 24).  
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The MTT cytotoxicity assay revealed that the decrease of hBD-2 inducibility was not due 
to cytotoxic side effects of the inhibitors as seen with Triton-X. 
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Figure 24: Effects of MAPkinase inhibitors and DMSO on cytotoxicity. Caco-2 cells were treated 
after incubation with the reagents, with MTT as described in Methods. Results are shown 
as a percentage of viable cells compared to untreated cells (DMEM). Data are mean ± SD 
of two experiments performed in duplicate. 
 
5.4 Determination of the hBD-2 inducing factor of E. coli Nissle  
Secondly, the present study placed emphasis on the determination of the hBD-2 inducing 
factor of the bacterial strain E. coli Nissle. We focused our search on the elucidation of the 
role of certain cell wall components (e.g., lipopolysaccharide, adhesins, K5-capsule) as 
well as secreted (e.g., microcins) or shed (e.g., flagella) factors (see Fig. 8) which might be 
responsible for the stimulatory effect regarding hBD-2. 
LPS responsiveness 
The following experiment was initiated to define whether the specific E. coli Nissle LPS 
plays a role in the hBD-2 induction by the E. coli Nissle strain. We compared LPS respon-
siveness among four human intestinal epithelial cell lines (Caco-2, T84, SW480 and 
SW620) which we demonstrated as expressing all TLR´s and adaptor molecules relevant 
for LPS signalling. We cultivated cells with 0.1, 0.5, 1 and 5 µg/ml LPS (E. coli serotype 
O111:B4) or E. coli Nissle LPS respectively. The expression of IL-8 was measured in su-
pernatants of cells stimulated with 1 µg/ml LPS or EcN-LPS.  
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In all cell lines, neither LPS concentration had any influence on hBD-2 expression (data 
shown only for 1µg/ml LPS in Table 11). Two cell lines released smaller (Caco-2 and 
SW480 cells) amounts of IL-8 and two cell lines higher (T84 and SW620 cells) amounts of 
IL-8, as determined by ELISA (Table 13). In Caco-2 cells, IL-8 generation was slightly 
upregulated after stimulation with EcN-LPS and even more so with LPS. In contrast, with 
T84 cells neither of the two LPS types could induce IL-8 protein expression. Surprisingly, 
SW480 cells responded to LPS stimuli with an 8-fold IL-8 increase of the unstimulated 
value and even 16 fold by E. coli Nissle LPS. 
 
Table 13: LPS responsiveness of IEC´s. The four cell lines were stimulated with 1 µg/ml LPS 
and relative hBD-2 mRNA expression was determined via RT-PCR. IL-8 (ng/ml) se-
creted into the cell culture supernatant was measured by ELISA. Values represent 
means ± SD of three (for hBD-2) and of two experiments (for IL-8). 
Cell line Treatment hBD-2 mRNA expression IL-8 protein expression 
 
Caco-2 Unst. 
EcN-LPS 
LPS 
0 
1 ± 0.1 
1.4 ± 0.5 
16.7 ± 7.3 
36.6 ± 0.9 
53.6 ± 0.9 
T84 Unst. 
EcN-LPS 
LPS 
0 
0 
0 
198.5 ± 147.4 
105.9 ± 26 
243.6 ± 0.4 
SW480 Unst. 
EcN-LPS 
LPS 
0 
0 
0.5 +/- 0.8 
10.7 ± 14.6 
166 ± 77.6 
81.9 ± 19.1 
SW620 Unst. 
EcN-LPS 
LPS 
0 
0 
0 
122 ± 14.6 
345.8 ± 65.7 
151.5 ± 8.6 
 
SW620 cells showed only after stimulation with E. coli Nissle LPS an almost 3-fold 
upregulation of IL-8, which was missing with the standard LPS tested. 
In summary, LPS is not responsible for inducing hBD-2 in intestinal epithelial cells, but 
shows a diverse pattern of responsiveness regarding IL-8 expression in the epithelial cells. 
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Bacterial DNA 
Since Caco-2 cells constitutively express TLR-9 mRNA they might have the ability to re-
spond to the respective ligand of CpG-rich bacterial DNA. To explore the potential effect 
of bacterial DNA on hBD-2 promoter activation, Caco-2 cells were treated for 4.5 h with 
25 µg/ml DNA isolated from E. coli Nissle and two different artificial immunostimulatory 
oligodeoxynucleotides (ISS-ODN) as positive and negative control (see Methods). Neither 
bacterial DNA nor ISS-ODN had any effect on hBD-2 promoter activation.  
Stability of hBD-2 inducing factor activity in E. coli Nissle supernatant 
To assess whether the hBD-2 inducing factor exhibits heat-sensitivity, the bacterial super-
natant was heated for 20 min at 100 °C. Compared to the stimulation by supernatant from 
heat-killed bacteria (set at 100 %) hBD-2 promoter activity was not reduced remarkably 
after the boiling treatment (91.1 ± 18.2 %).  
Next, we investigated whether the hBD-2 activating molecule is a protein by treating the E. 
coli Nissle supernatant with proteinase K. HBD-2 promoter activity was reduced from 100 
% (untreated E. coli Nissle supernatant) to 28.4 ± 3.4 % when the bacterial supernatant was 
pretreated with proteinase K. TSB media treated with proteinase K, boiled for 20 min and 
added to the cells for 4.5 h had no negative effect on cell viability, showing that the pro-
teinase was really inactivated after the heat treatment. These data indicate that the hBD-2 
inducing factor in the supernatant is a heatstable and proteinase-sensitive molecule. 
HBD-2 promoter activation by mutant bacteria 
To clarify which factor in the bacteria supernatant is responsible for hBD-2 induction, 
Caco-2 cells were stimulated with either wild-type EcN or isogenic mutants with deletions 
of known fitness factors (e.g., adhesins, microcin, iron siderophores or flagellin). Only the 
supernatant of the flagellin mutant (EcNsn ΔfliC), which lacks the production of the flagel-
lin filament protein, showed a decrease in activation capacity. The other mutants displayed 
no change compared to wild-type E. coli Nissle (EcNsn) (Fig. 25a).  
To focus further on the role of flagellin in E. coli Nissle signalling two other flagellin mu-
tants (ΔflgE and ΔfliA) were constructed. Stimulation of Caco-2 cells with supernatants of 
the flagellin mutants’ ΔflgE (hook mutant i.e. “anchor” protein of the flagellum) as well as 
ΔfliA (sigma factor) resulted in a similar decrease in hBD-2 promoter activation (wild-type 
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EcNsn: 15.5 ± 5.2 fold, ΔflgE: 2.7 ± 0.7 fold, ΔfliA: 2.1 ± 1.0 fold). Consistent with this, 
the flagellin mutants of E. coli Nissle completely failed to stimulate hBD-2 mRNA expres-
sion (Fig. 25b). 
In order to verify that this remarkable loss of hBD-2 induction by the flagellin mutants was 
specifically attributable to the lack of flagellin, deleted genes were complemented in trans 
by transforming the respective mutant with a recombinant plasmid harboring the corre-
sponding gene (= ΔfliCpDB2 and ΔflgEpDB3).  
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Figure 25: Effect of E. coli Nissle fitness factor mutants on hBD-2 expression. a) Transfected 
Caco-2 cells were incubated for 4.5 h with supernatants from various E. coli Nissle mutant 
strains. hBD-2 inducing activity was determined by the luciferase reporter gene assay. The 
data are means ± SD of three independent experiments assayed in duplicate. b) Induction 
of hBD-2 mRNA expression by flagellin-deficient (ΔfliA, ΔfliC and ΔflgE) and comple-
mented (ΔfliCpDB2 and ΔflgEpDB3) E. coli Nissle. Gene expression was analyzed by 
real-time PCR. The data represent means ± SD of four experiments in duplicate. 
a 
b 
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After complementation, the fliC and the flgE mutants regained their capacity to induce 
hBD-2 mRNA. Several attempts were made to clone the ΔfliA gene without success. 
Therefore, we continued our experiments only with the ΔfliC and ΔflgE complementants. 
Protein and functionality 
As a further proof for the loss of flagellin synthesis, LB swarmagar plates were inoculated 
with the different strains (Fig. 26a). Visually determined swarming was normal in case of 
DH5α and wild-type E. coli Nissle 1917 (EcN) strains. All flagellin mutants (ΔflgE, ΔfliC 
and ΔfliA) showed an abolished swarming. The complemented mutants displayed an inter-
mediate swarming (ΔfliCpDB2 and ΔflgEpDB3). 
 
 
a 
Figure 26: Analysis of flagellin-mutant and complemented E. coli Nissle strains. a) Characteriza-
tion of motility by swarming in semisolid agar. Cultures of the wild-type E. coli Nissle and 
the flagellar mutants and their complements were plated into wells punched into 0.3 % LB 
agar plates and incubated for 10 h at 37 °C. Lack of motility is indicated by growth re-
stricted to the spot of inoculation, whereas motility is indicated by growth throughout a 
larger circle. b) Flagellin expression assessed by Western blot analysis. Heat-killed over-
night bacterial cultures were subjected to SDS-PAGE electrophoresis, and flagellin expres-
sion was analyzed with H7 flagellin antiserum. Lane 1, EcN (wild type); lane 2, 
EcN∆flgEpDB3 (complemented ∆flgE mutant); lane 3, EcN∆fliCpDB2 (complemented 
∆fliC mutant); lane 4, EcN∆flgE; lane 5, EcN∆fliC; lane 6, EcN∆fliA. 
 
b
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This shows that the complementation with the flagellin or the hook gene respectively was 
successful regarding the regain of the hBD-2 inducing capacity but failed to accomplish 
the full motility function of the flagella. The lack of flagellin synthesis after the mutation 
was also confirmed by Western blot (Fig. 26b).  
Flagellin mutants (ΔflgE, ΔfliC and ΔfliA) lacked the bands specific to flagellin whereas 
complemented mutants (ΔfliCpDB2 and ΔflgEpDB3) displayed immunoreactivity.  
 
5.5 Identification and isolation of the bacterial hBD-2 inducing factor  
Flagellin might act in concert with other molecules, which may be also essential for proper 
hBD-2 induction. Thus, we had to investigate whether isolated flagellin is capable of suffi-
ciently inducing hBD-2, when the flagellin is seperated from other particles of the bacteria 
with stimulatory potential. The purity of the isolated E. coli Nissle flagellin was assessed 
by SDS-PAGE and Coomassie staining (Fig. 27). A clear band between 49 and 62 kDa 
was detectable after staining. After (NH4)2SO4 precipitation, dialysis and heat treatment a 
clear band presumably containing the flagellin was also seen.  
 
 
Figure 27: Analysis of isolated E. coli Nissle flagellin by Coomassie blue staining. SDS-PAGE 
analysis of the purified flagellin preparation by Coomassie brilliant blue. The relevant po-
sitions of the molecular mass standard (SeeBlue Plus 2, Invitrogen) are marked on the left 
or right (Multi Mark, Invitrogen). Lane 1 + 2, final step: flagellin isolate (1 and 0.5 µg/µl); 
lane 3, PBS (Blank); lane 4, final step: flagellin residue in supernatant; lane 5+6, pellet 
and turbid supernatant after heating to 65 °C and ultracentrifugation (100 000 x g) 
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Lane 4 showing the protein found in the supernatant from the last isolation step indicates 
that some flagellin residue was still present and not all of this protein was precipitated by 
the lower (NH4)2SO4 concentration. 
Analysis of the bacteria isolate by mass spectrometry was kindly performed by Dr. Jürgen 
Harder (University of Kiel). The detected molecular mass of the flagellin confirmed the 
expected flagellin size of 60.81 kDa (Fig. 28).  
 
 
 
 
 
 
 
 
 
 
Figure 28: Mass spectrometric analysis of isolated E. coli Nissle flagellin. The sample was diluted 
1:10 in 50 % acetonitrile containing 0.02 % formic acid and analyzed by electrospray mass 
spectrometry.  
 
 
Figure 29: Dose response of hBD-2 promoter activity by E. coli Nissle flagellin stimulation. Caco-
2 cells were stimulated for 4.5 h with 0, 0.1, 1, 5 or 10 µg/ml of isolated flagellin. The 
hBD-2 inducing activity was determined by using a luciferase reporter gene assay with 
basal activity of the promoter set at 1. The data are means ± the SD of three independent 
experiments in duplicate. 
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As shown in Fig. 29, the isolated E. coli Nissle flagellin induced a dose-dependent increase 
of hBD-2 promoter activation. 
 
Moreover, the preincubation of E. coli Nissle culture supernatant with H1 flagellin antise-
rum inhibited hBD-2 mRNA expression by almost 70 % (Fig. 30). Consistent with this 
observation, the hBD-2 induction by isolated H1 flagellin was inhibited by 50 % in the 
presence of the corresponding antiserum. The antibody alone had no effect on hBD-2 
mRNA expression. 
 
           
Figure 30: Effect of anti-H1 flagellin antiserum on activity of flagellin and E. coli Nissle super-
natant. Isolated flagellin (0.1µg/ml) or E. coli Nissle supernatant (grey columns) were 
mixed with H1-flagellin antiserum (1:100) in FCS-antibiotic-free DMEM and added to 
Caco-2 cells. The untreated flagellin and supernatant were used as a reference (black col-
umns). After 6 h of exposure, RNA was isolated followed by determination of hBD-2 
mRNA expression by real-time PCR. The data are means ± the SD of three experiments in 
duplicate. 
 
Isolation of different flagellins 
Since flagellins from different Salmonella species have been shown to induce hBD-2 ex-
pression in epithelial cells (Ogushi 2001), we isolated flagellin from Salmonella enterica 
serovar Enteritidis, as well as from the apathogenic E. coli strain ATCC 25922 and the E. 
coli strain JM109 as controls.  
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The genome structure of E. coli Nissle was shown to resemble closely that of the uropa-
thogenic E. coli CFT073∆hly strain (see Appendix).  
Hence, we compared the hBD-2 inducing capacity of the serotype-identical CFT073∆hly 
with that of the E. coli Nissle flagellin. Only flagellin from S. enteritidis induced hBD-2 
mRNA significantly (Fig. 31a + b) in contrast to the flagellin of the apathogenic E. coli 
strain ATCC 25922 (Fig. 31b) that lacked an induction.  
 
 
    
 
 
Figure 31: Flagellin isolates induce hBD-2 mRNA expression. a) Qualitative hBD-2 mRNA ex-
pression induced by E. coli Nissle flagellin. The results of agarose gel electrophoresis (2 
%) of RT-PCR products from Caco-2 cells incubated for 6 h with medium (lane 1), E. coli 
Nissle supernatant (lane 2), E. coli Nissle flagellin (lane 3) or S. enteritidis flagellin (lane 
4) are shown. hBD-2 fragments are given in the upper panel, GAPDH controls of each 
sample are shown in the bottom panel (molecular mass marker, 100 bp). The product sizes 
were as follows: hBD-2, 172 bp; and GAPDH, 360 bp. b) Quantitative hBD-2 mRNA ex-
pression induced by flagellins from different bacterial strains. Caco-2 cells were stimulated 
for 6 h with flagellin isolates from E. coli Nissle, Salmonella enteritidis, CFT073∆hly, E. 
coli ATCC 25922 and E. coli JM109. hBD-2 mRNA expression was assayed by RT-PCR. 
The data are means ± the SD of three experiments in duplicate. 
 
The E. coli JM109 flagellin of the serotype H48 hardly induced hBD-2, whereas 
CFT073∆hly flagellin was able to induce hBD-2 but not as strongly as the flagellin of E. 
coli Nissle (Fig. 31b).  
 
 
a b
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The isolated flagellins were also subjected to Western blot analysis with an anti-H1 antise-
rum. Since serologically distinct flagella possess a highly conserved primary sequence of 
flagellin monomers within the exposed central region, all flagellins could be detected by 
Western blotting despite their different flagellin serotypes (Fig. 32). Interestingly, the 
CFT073∆hly flagellin of the uropathogenic E. coli appeared to exhibit a smaller molecular 
size than the EcN flagellin despite having the same flagellin serotype. 
 
 
Figure 32: Western blot of flagellins from different bacterial strains. Flagellins from E. coli Nissle 
(lane 1), Salmonella enteritidis (lane 2), CFT073∆hly (lane 3), and E. coli ATCC 25922 
(lane 4) were separated by electrophoresis on SDS-PAGE gels and incubated with H1 
flagellin antiserum overnight. 
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6 DISCUSSION 
The evidence of a major role of the luminal flora in the development of IBD together with 
the effective use of antibiotics in the treatment of CD patients gave rise to alternative 
strategies to manipulate the intestinal flora. The administration of probiotics appeared to be 
a promising approach as it is principally free of systemic side effects. The question arose 
concerning how probiotics exert their numerous beneficial effects. These can hardly be 
explained by a unifying hypothesis that is based on a single quality or mechanism and re-
mains valid for all microorganisms exerting one or the other effect mentioned before. The 
objective of the present study was to gain more insight into the influence of probiotics on 
the epithelial barrier function with respect to the induction of the antimicrobial peptide 
hBD-2. We therefore investigated the ability of probiotics to induce this defensin and ex-
amined essential signalling pathways and the transcriptional regulation. Our aim was fur-
ther, to clarify which bacterial factor of the probiotic strain E. coli Nissle was responsible 
for inducing hBD-2 gene expression in intestinal epithelial cells. 
 
6.1 Different cell lines as a model to investigate hBD-2 expression 
To investigate whether different intestinal epithelial cell lines similarly express hBD-2 
upon stimulation with E. coli Nissle or IL-1β we used four well-characterized human colo-
nic cancer cell lines i.e. Caco-2, T84, SW480 and SW620. We chose to use cultured 
epithelial cell lines instead of freshly isolated enterocytes for several reasons. First, in con-
trast to harvested enterocytes, cultured epithelial cells are not contaminated by the presence 
of other cell populations, intestinal bacteria or endotoxins that could complicate data inter-
pretation. Second, the viability of harvested enterocytes in vitro would have been limited 
and the harvesting process might have caused cell injury.  
 
The hBD-2 inducing effect varied amongst the different intestinal cell lines tested. The 
highest expression pattern was measured in Caco-2 cells in the case of both stimulants. IL-
8, which is induced upon contact with gram-negative bacteria, served as a control response 
gene and was also differentially strong secreted. This confirms earlier results from 
Schuerer-Maly et al (1994) who found a variable IL-8 response depending on the cell line 
tested with a missing IL-8 release from T84 cells upon stimulation with IL-1β. Treatment 
with E. coli Nissle supernatant had little effect on IL-8 secretion by T84 cells in contrast to 
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Caco-2, SW480 and SW620 cells, which released IL-8 significantly. This diversity may be 
related to differences in the recognition of specific hBD-2 but not IL-8 inducing ligands 
and variable signalling events upstream of NF-κB.  
 
Taken together these results suggest Caco-2 cells as a model best suiting further investiga-
tions on hBD-2 expression induced by bacteria. However, the expression of antimicrobial 
peptides may not necessarily reflect the expression in normal cells of the human intestine. 
Successful culture of small intestinal mucosa specimens obtained from patients with IBD 
has been previously reported by Reimund et al (1996). Thus, we also tried to culture biop-
sies freshly obtained from either control or UC patients to imitate more closely the in vivo 
state. Previous in vitro studies of the function and metabolism of intestinal mucosa have 
been hampered by the rapid epithelial destruction which occurs after excision of intestinal 
mucosal samples and detachment from the basal membrane. Likewise, our model which 
was intended to be closer to the in vivo state than our experiments with cancer cell lines 
failed to demonstrate an hBD-2 inducing effect by E. coli Nissle or IL-1β treatment, 
probably also due to necrosis. 
Considering the malignant characteristics of Caco-2, T84, SW480 and SW620 cells, it is 
tempting to speculate that the expression of antimicrobial peptides could be also due to 
abnormal Paneth cell-like functions expressed by these cells in culture. 
 
6.2 TLR expression  
The Toll-like receptor expression pattern in different intestinal cell lines was investigated 
to gain insight for possibly important bacterial components playing a role in hBD-2 induc-
tion. Since all cell lines expressed the investigated range of TLR´s and the associated adap-
tor molecules, we could not exclude any of the known pathogen-associated molecular pat-
tern (PAMPs) as irrelevant for E. coli Nissle signalling. We did not compare the quantita-
tive expression of TLR´s in the four cell lines, since our main interest was the identifica-
tion of the bacterial inducers or ligands according to the “all-or-nothing” principle. The 
varying expression of IL-8 and hBD-2 in the different cell lines is obviously not related to 
a cell type specific TLR expression pattern since the receptors were constitutively ex-
pressed in each of the tested cell lines. 
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6.3 Time- and dose-dependent hBD-2 expression in Caco-2 cells 
Several studies have demonstrated that IL-1β is a potent inducer of hBD-2 expression 
(Harder 2000; McDermott 2003). Furthermore, the up-regulation of hBD-2 expression is 
detected in surrounding areas of inflammation, but not adjacent non-inflamed regions (Liu 
1998, Mathews 1999). Our data identify the proinflammatory cytokine IL-1β as a major 
agonist for hBD-2 induction in Caco-2 cells, which was found to up-regulate hBD-2 
mRNA in a time- and dose-dependent manner. 
 
Interestingly, hBD-2 expression in Caco-2 cells depended on the degree of cell differentia-
tion or rather growth duration before stimulation. Since treatment of confluent cells with 
IL-1β resulted in a diminished hBD-2 expression we used subconfluent cells for our ex-
periments. Eckmann et al (1993b) explains that more differentiated cells are hyporespon-
sive, which reflects the physiological situation. Controversial to our results Hase et al 
(2002) reported a shared coordination of the antimicrobial protein cathelicidin LL-
37/hCAP18 gene expression in colon epithelium with augmented cell differentiation. Ca2+ 
induced differentiation of keratinocytes was also shown to increase hBD-2 expression in 
response to IL-1α stimulation (Liu 2002). These results suggest that the varying influence 
of differentiation on gene expression should also be taken into account when investigating 
hBD-2 inducibility in different cell models.  
 
Based on our previous studies with E. coli Nissle, we further investigated whether other 
probiotic strains might also have the capacity to stimulate hBD-2 expression. A more or 
less distinct time- and dose-dependent hBD-2 induction by the diverse probiotic strains 
tested was determined; some strains also lacked any hBD-2 inducing effect. These results 
suggest that different strains of probiotic bacteria may exert different effects based on spe-
cific capabilities and enzymatic activities, even within one species. L. plantarum 299v for 
instance induced mucin gene expression (Mack 1999) thereby inhibiting adherence of en-
teropathogenic and enterohemorrhagic E. coli strains to epithelial cells. Furthermore, this 
strain also reduced elevated intestinal permeability due to E. coli exposure in rats (Fak 
2006). However, in our experiments L. plantarum exerted only restricted hBD-2 transcrip-
tion activation.  
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The probiotic VSL#3, a preparation consisting of 8 different bacterial species, seems to be 
effective in the treatment of pouchitis, which might be caused at least in part by the induc-
tion of the antimicrobial defence system of the gut which we determined. This hypothesis 
is confirmed by recent unpublished investigations of Otte et al (2005) who found that 
VSL#3, L. acidophilus and E. coli Nissle significantly induced the expression of diverse 
antimicrobial peptides (AMPs) such as hBD-2, -3 and -4, LL-37 and RNAse7. Another 
proof for a beneficial effect of VSL#3 via an induction of AMPs is given by Wang et al 
(2003) who specifically investigated the VSL#3 strain Bifidobacterium longum, which 
stimulated significantly hBD-2 gene expression in cultured human intestinal epithelial 
cells.  
 
6.4 Bacterial supernatant is more potent than bacterial pellet to induce hBD-2 
We further investigated whether Caco-2 cells express hBD-2 in the presence of soluble 
factors from the bacterial culture supernatant or predominantly in direct contact with the 
heat-killed bacteria. Indeed, the supernatant of bacteria expressed relevant hBD-2 inducing 
capacity with a maximal induction between 6 h and 12 h that was greatly attenuated after 
24 h of incubation. This was a delayed response compared to the kinetic of hBD-2 expres-
sion mediated by the bacterial pellet. Moreilhon et al (2005) analyzed the influence of bac-
terial supernatant on epithelial cells using a pangenomic microarray. He determined also a 
diminished transcriptional response of genes implicated in inflammation and apoptosis to 
Staphylococcus aureus supernatant when stimulation exceeded 9 h up to 24 h.  
 
Interestingly, when comparing the extent of hBD-2 induction by bacterial pellet or super-
natant, a strikingly higher activation by soluble or shed products in the supernatant was 
determined by reporter gene assay, which was further confirmed on the mRNA level. 
However, this difference was not a general characteristic as two out of three supernatants 
from other probiotics, induced similarly strong hBD-2 than the corresponding pellet. The 
expression of chemokines e.g., CCL20, interleukins (IL-1, IL-6 and IL-8) and activation of 
NF-κB pathways was also shown to be upregulated in epithelial airway cells when treated 
with bacterial supernatant of S. aureus, but was only marginally altered after direct bacte-
rial contact (Moreilhon 2005).  
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Several studies have further demonstrated that E. coli Nissle, VSL#3 or L. acidophilus 
LA1 respectively, were able to inhibit adhesion to and invasion of human intestinal epithe-
lial cells by enteroinvasive pathogens via a secreted component independent from any di-
rect physical contact (Bernet 1994; Madsen 2001; Boudeau 2003; Altenhoefer 2004). This 
effect might be due to non-specific steric hindrance of the apical enterocytic receptors for 
pathogens (e.g. by biofilm formation) and/or additional secretion of hBD-2 which further 
kills pathogens. Our data strongly suggest that a soluble factor or factors secreted by E. 
coli Nissle might be the predominant means by which hBD-2 transcription is regulated. 
Still we cannot exclude that bacterial lysis caused by the heat-killing procedure might re-
sult in a release of cytosolic proteins into the medium.  
 
Focussing on the heat-treatment of our bacteria, the definition that probiotics have to be 
viable microorganisms to exert their beneficial effects might need to be revised, since bac-
teria, which did not survive, still exerted immunostimulatory effects. Dead bacteria could 
have an even stronger effect than living microorganisms. This assumption could be sup-
ported considering the capacity of dead lactobacilli to compensate lactase insufficiency in 
lactose maldigestion (de Vrese 2001) since dead bacteria in the small bowel are ingested 
and release β-galactosidase into the upper intestine. In addition, bacteria killed by irradia-
tion, leaving the cell wall intact and therefore enabling protection during gastric transit, 
could also exert positive immunostimulatory effects (Rachmilewitz 2004). 
 
6.5 Transcriptional regulation of hBD-2 expression by probiotics 
NF-κB and AP-1 both participate in the regulation of a variety of genes including those 
encoding proinflammatory cytokines that are involved in the first line of defense to a vari-
ety of insults. Consequently, we concentrated our investigations on these two transcription 
factors although the hBD-2 gene is known to also include consensus sequences for the 
transcription factors STAT and NF-IL-6 (Tsutsumi-Ishii 2002).  
 
The transcription factors NF-κB and AP-1 appeared to be both necessary for full hBD-2 
promoter activation by the bacterial supernatant of E. coli Nissle as well as by L. fermen-
tum, Pediococcus pentosaceus and L. acipdophilus similar to our previous findings with E. 
coli Nissle pellet (Wehkamp 2004). Tomita (2002) has also suggested that NF-κB and AP-
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1 as well as intracellular calcium are essential for LPS-mediated hBD-2 expression in a 
human airway cell line (LC-2/ad). Diamond et al (2000) have demonstrated that transcrip-
tion of the bovine β-defensin TAP gene is cooperatively regulated by NF-κB and NF-IL-6 
in response to LPS. Since the promoter activation by E. coli Nissle supernatant depended 
in the present study also partly on AP-1, synergistic effects between NF-κB and AP-1 seem 
to be also quite likely. We suggest that AP-1 is not able to elicit hBD-2 gene activation 
without the contribution of NF-κB.  
 
Many genes are regulated through synergistic effects of these two transcription factors, 
which were first described by Stein et al (1993), still we did not further investigate whether 
NF-κB and AP-1 interact directly or exert an additive effect on the promoter. In contrast to 
our findings, Tsutsumi-Ishii et al (2003) determined that AP-1 was not crucial to the LPS-
mediated transcriptional regulation of the hBD-2 gene in mononuclear phagocytes since 
they determined no significant differences in promoter activity after deletion of the AP-1 
binding site. They demonstrated further that the two tandemly repeated binding sites for 
NF-κB (at -577 and -188) were essential for the LPS responsiveness of the hBD-2 gene. 
Adjacent binding sites for NF-IL-6 within the hBD-2 promoter did not contribute to the 
LPS-induced hBD-2 transcription. In particular, the NF-κB binding site closest to the tran-
scription start was shown to have the highest impact on hBD-2 promoter activation by E. 
coli Nissle or H. pylori respectively (Wehkamp 2004, Wada 2002).  
We emphasize that despite the clear role of NF-κB and AP-1 in hBD-2 induction mediated 
by our tested probiotics a certain impact of other transcription factors cannot be excluded. 
In addition, posttranslational modifications might still interfere with the functionally rele-
vant expression of hBD-2 protein.  
 
The prominent role of NF-κB for the hBD-2 induction by diverse stimuli is listed in the 
introduction part (page 19). Because IECs are surrounded by commensal bacteria and are 
the first cells affected by pathogens, the effect of bacteria on NF-κB activation in IECs has 
been intensively examined. Savkovic et al (1997) reported that T84 cells infected with 
enteropathogenic Escherichia coli secrete IL-8 through an NF-κB-dependent mechanism. 
However, IL-8 gene expression was not induced in IECs infected with non-pathogenic E. 
coli, suggesting that IECs discriminate between non-pathogenic and pathogenic bacteria 
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with respect to NF-κB activation (Savkovic 1997). Hobbie et al (1997) have demonstrated 
that Salmonella infection of IECs triggers IκBα degradation and IL-8 release.  
A number of invasive bacteria induce NF-κB dependent chemokines in a wide variety of 
IEC lines (Kagnoff 1997). The requirement of bacterial invasion is controversial, since 
non-invasive bacteria can also trigger NF-κB activation (Eaves-Pyles 1999) as we have 
also demonstrated in the present study. 
 
Probiotic bacterial strains, relevant for industrial purposes, have been frequently presented 
as inhibitors of proinflammatory responses with a concomitant absence of NF-κB activa-
tion. For example, the probiotic strain L. casei was suggested to reduce inflammation by 
enhancing the activation of PPARγ, which exerts an anti-inflammatory role by the inhibi-
tion of the NF-κB pathway. Hence, L. casei also diminished LPS-induced expression of 
COX-2, IL-8 and TLR-4 (Eun 2006). In contrast to the widely claimed attenuation of in-
flammatory responses by probiotics on one hand and the strong proinflammatory effect of 
pathogens, E. coli Nissle might induce a proinflammatory response just above the “thresh-
old level” preventing an inflammatory outcome, but inducing a higher alertness of the in-
testinal epithelial cells host defense system.  
 
6.6 Signalling pathways involved in hBD-2 expression mediated by probiotics 
In an attempt to identify some key elements that constitute the link between stimulation 
with probiotics and the expression of hBD-2, we evaluated whether three major subgroups 
of MAP kinases, ERK½, p38 and JNK were activated by these probiotics. The ERK sig-
nalling module was the first MAP kinase cascade to be characterised. Although, its pri-
mary role has long been thought to be restricted to cell growth and proliferation, it has be-
come clear that several inflammatory processes involve ERK½ activation. ERK-1 deficient 
mice, for instance, expressed defective thymocyte maturation and reduced expression of α 
and β chains of the T cell receptor (Pages 1999). This indicates that ERK activation is cru-
cial for T cell activation and appears to be mediated by the AP-1 family of transcription 
factors. The JNK signalling pathway is activated by cell stress and is involved in the regu-
lation of cell proliferation and apoptosis. It appears in parallel with ERK½ to be essential 
for AP-1 activation due to stress and exposure to various cytokines. JNK has been impli-
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cated in a large variety of pathological conditions, including cancer, stroke and inflamma-
tory disorders.  
 
Murine p38 MAP kinase was first identified in 1994 as a kinase activated in response to 
bacterial lipopolysaccharide (LPS) (Han 1994). Extracellular stimuli of p38 include a vari-
ety of cytokines (IL-1, IL-2, IL-18, TGF-β, TNF-α etc.) and a number of pathogens that 
activate p38 through the different Toll receptors. These involve LPS, peptidoglycan and 
enterotoxin from Staphylococcus ssp. as well as growth factors like GM-CSF (granulocyte 
macrophage-colony stimulating factor). The downstream targets of p38 are either other 
kinases or transcription factors such as ATF-2, which can form heterodimers with Jun tran-
scription factors (both belong to the subfamily of AP-1). The MAP kinase p38 has also 
been associated with activation of NF-κB, as a p38 inhibitor (SB203580) attenuated NF-κB 
dependent transcription (Bergmann 1998). 
 
Previous experiments regarding signalling events upstream of NF-κB mediated by whole 
E. coli Nissle bacteria (Wehkamp2004) revealed the explicit involvement of the c-Jun N-
terminal kinase (JNK), whereas in the present study the supernatant of E. coli Nissle trans-
mitted its signal also via ERK½ and to a smaller extent via p38. L. fermentum and Pedio-
coccus pentosaceus induced hBD-2 promoter activation also via the three MAP kinases 
although the involvement of ERK½ and JNK seemed to be less pronounced than after E. 
coli Nissle supernatant stimulation. Downstream, ERK½ may be involved in the regulation 
of NF-κB through MEK, which has been shown to activate both IKK-α and IKK-β (Na-
kano 1998). Moon et al (2002) described also a role for ERK½ in IL-1α mediated hBD-2 
induction in human middle ear epithelial cells. 
 
Using an hBD-2 promoter construct with a mutated AP-1 binding site, which creates an 
almost exclusive activation via NF-κB, revealed that p38 might be of no importance for the 
NF-κB mediated activation of hBD-2 expression. The moderate inhibitory influence of 
SB203580 on p38-mediated hBD-2 activation suggests that p38 might play a more deci-
sive role for AP-1 activation leading to hBD-2 transcription.  
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Here we demonstrate that the stimulation of the MAP kinase pathways by probiotics is 
directly responsible for the probiotic-induced activation of the AP-1 and NF-κB transcrip-
tion factors and subsequent synthesis of hBD-2. 
Is it possible that both transcription factors are activated by the same MAP kinases? 
The answer is to be found in the upper signalling part, where the pathway diverges at the 
level of MEK kinases or MAP kinase kinases (MEKK´s 1-3), which further activate by 
phosphorylation:  
a) MKK´s leading to the activation of p38 and JNK and additional members of the AP-1 
family or  
b) I-κBα kinases which regulate transient NF-κB activation (Hobbie 1997).  
Thus, common pathways between NF-κB and AP-1 might exist, although the exact links of 
mutual activation via MAP kinases remain elusive. A probable synergy between NF-κB 
p65 and Jun/Fos of the AP-1 family might have important implications for both immune 
and inflammatory responses, since both transcription factors are responsible for immediate 
early gene expression.  
Our results indicate that distinct probiotics share with several bacterial pathogens including 
H. pylori, enteropathogenic (EPEC) and enterohaemorrhagic E. coli (EHEC) the ability to 
activate MAP kinase signalling pathways and epithelial proinflammatory responses such as 
IL-8, but in a noninvasive manner. However, considering the great variety of species and 
strain characteristics, it becomes clear that a proven probiotic effect on one strain or spe-
cies cannot be transferred to another strain or species.  
 
6.7 Analysis of the hBD-2 inducing factor in the E. coli Nissle supernatant  
6.7.1 LPS 
The major molecular determinant of gram-negative bacteria responsible for NF-κB activa-
tion is the glycolipid lipopolysaccharide (LPS) which is found in high concentrations in the 
colon. This bacterial product signals through the IκB/NF-κB system by binding to its cell 
surface toll-like receptor (TLR) 4 and co-receptor MD-2 which then utilizes downstream 
components of the IL-1 signalling cascade (Zhang 2001; Faure 2000). Haller and col-
leagues (2002) have demonstrated that, following recognition of LPS by TLR4, the non-
pathogenic commensal enteric bacteria Bacteroides vulgatus activates NF-κB nuclear 
translocation. This is followed by an induced proinflammatory gene expression in IEC 
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lines as well as in primary enterocytes. Since E. coli Nissle exhibits a special kind of LPS 
of the semi-rough type, it might mediate its beneficial effect of hBD-2 induction by this 
structure.  
 
Although LPS has been reported to stimulate hBD-2 expression in gingival tissue and epi-
dermal keratinocytes (Mathews 1999; Harder 1997a) other studies demonstrated that LPS 
did not trigger hBD-2 gene transcription in colonic epithelial cell lines (O´Neil 1999, Fahl-
gren 2003). Accordingly, we failed to detect hBD-2 after exposure of Caco-2 cells to either 
a control LPS (E. coli O111:B4) or E. coli Nissle LPS. The lack of response was not due to 
the absence of LPS-binding protein in our FCS-free experimental conditions, since addi-
tion of serum did also not induce hBD-2 expression. Furthermore, the absence of expres-
sion of the LPS receptor CD14 in the investigated cell lines cannot account for the missing 
hBD-2 induction. Though we confirmed only CD14 mRNA expression and not the func-
tionally relevant CD14 protein expression a lack of the latter seems to be unlikely.  
 
The failure of LPS to induce hBD-2 expression in Caco-2 cells may reflect an adaptation 
of the intestinal epithelial cells to the high levels of bacterial LPS that are normally present 
in the human colon compared to the lower levels in oral mucosa.  
How is it then possible that LPS can exert the hBD-2 inducing effect in other tissues?  
In vivo LPS penetrating deep into the skin might be detected by macrophages. These could 
serve as intermediators by the release of cytokines, which stimulate the hBD-2 expression 
(Liu 2002). When determining the IL-8 response on LPS stimuli we detected no increase 
of IL-8 release from T84 cells. Caco-2 cells secreted a 2-3 fold IL-8 release upon LPS 
stimuli compared to unstimulated cells similarly to SW620 cells. Schuerer-Maly et al 
(1994) also determined a missing IL-8 response of T84 cells upon LPS stimulation. In con-
trast to our results, Caco-2 cells were completely unresponsive to LPS regarding IL-8 se-
cretion. SW620 cells but on the other hand were reported to be highly LPS responsive, 
which we found to be only weak. However, in our study, the IL-8 responsiveness to LPS 
was strong in SW480 cells.  
Suzuki et al (2003) explains the differences between the cell responses by a classification 
of commonly studied intestinal epithelial cell lines into three different types of LPS re-
sponsiveness, TLR4 expression and the effect of priming with interferon-γ (IFN-γ).  
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Accordingly, Caco-2 cells belong to the phenotype, which is characterized by hyporespon-
siveness to LPS, and reduced TLR4 protein expression, which is not influenced by pre-
treatment with IFN-γ. SW480 cells in contrast, exhibit a highly LPS-responsive phenotype 
and a clear TLR4 protein expression on the surface even in unprimed condition, whereas 
the rather LPS-hyporesponsive HT-29 cells, respond to LPS by IFN-γ induction via an 
increase of LPS uptake, MD-2 mRNA and intracellular TLR4 protein expression.  
Furthermore, the degree of differentiation might also account for differences in LPS re-
sponsiveness, since PMA-treated leukemic THP-1 cell lines differentiate to a monocyte-
like phenotype, which leads to an upregulation of TLR´s and an increased sensitivity to 
LPS (Zarember 2002). 
 
6.7.2 Immunostimulatory bacterial DNA 
We determined a constitutive expression of TLR-9 in Caco-2 cells which might thus have 
the ability to respond to CpG-rich bacterial DNA. Similar to the Toll-like receptor ligand 
LPS, immunostimulatory DNA sequences (ISS-DNA) exert a broad range of activities on 
the mammalian innate immune system. Numerous studies have shown that bacterial DNA 
elicits a NF-κB response, perpetuates inflammation and downregulates the antibacterial 
defence effectors HBD-1 and LL-37 (Obermeier 2005, Islam 2001). Akhtar et al (2003) 
provide evidence that exposure of HT-29 cells to E. coli DNA resulted in an exclusive AP-
1 mediated induction of IL-8 mRNA and protein without the involvement of NF-κB. Sev-
eral studies reported a diminished pathogen-induced proinflammatory response following 
the immunostimulatory effects exerted by probiotic DNA (Jijon 2004, Ewaschuk 2006). 
VSL#3 DNA exhibited for instance inhibitory effects on IL-8 secretion, p38 and NF-κB 
activation in HT-29 cells and reduced mucosal TNFα and IFN-γ secretion from IL-10-
deficient mice after the oral intake of DNA (Jijon 2004). Furthermore, VSL#3 DNA pro-
tected mice from experimentally induced colitis when given intragastrically or subcutane-
ously (Rachmilewitz 2004). The administration of DNA from Escherichia coli also ame-
liorated colitis.  
 
For our experiments we used phosphothioate ODNs as positive controls, which are nucle-
ase resistant and can be as much as 200-fold more potent than natural phosphodiesters 
ODNs (Krieg 1995). Genomic DNA isolated from E. coli Nissle had no influence on hBD-
Discussion   86 
2 promoter activation and also the synthetic oligonucleotide analogs of immunostimulatory 
DNA sequences lacked to induce hBD-2 in Caco-2 cells. As a proof for intact immu-
nostimulatory DNA, we could have monitored its effect on IL-8 production, which was 
reported to be increased in human embryonic kidney cells upon stimulation with CpG 
DNA (Bauer 2001). However, despite a potentially positive IL-8 response by Caco-2 cells 
to the bacterial DNA stimuli one cannot generally infer an association between an IL-8 
induction and an hBD-2 induction.  
 
Another reason for the missing stimulation of hBD-2 expression could be that signalling of 
CpG DNA might occur in intracellular compartments, since immobilized CpG DNA has 
been reported to be inactive (Krieg 1995). Further, stimulatory activity of CpG DNA was 
enhanced by lipofection (Gursel 2001); therefore, it might be possible, that our DNA could 
not initiate any immune reaction due to a defective internalization, which occurs normally 
via a clathrin-dependent endocytic pathway. TLR9 is located in the endoplasmatic reticu-
lum (ER) of resting cells, but it translocates to a CpG DNA-containing lysosomal com-
partment for ligand binding and signal transduction (Latz 2004). If the proper distribution 
of TLR9 between the ER and the lysosomal compartment is not ensured, the binding of the 
CpG motif by TLR9 might be decreased and the successive signal transduction fails to be 
initiated. Nevertheless, according to Latz et al (2004) a small portion of TLR9 becomes 
surface accessible after exposure to CpG DNA, suggesting that a certain, albeit small 
DNA-related response could be transmitted by TLR9. 
 
6.7.3 Heat and proteinase treatment 
In our next attempt to identify the characteristics of our hBD-2 inducing component, we 
either boiled the supernatant or treated it with proteinase K. The heat treatment caused no 
significant change in hBD-2 induction capacity proposing a heat-stable factor to be respon-
sible. This factor was revealed to consist mainly of protein, since protein digestion resulted 
in a strong down regulation of the normal hBD-2 response by Caco-2 cells. 
 
6.7.4 Mutant E. coli Nissle strains 
To characterize the responsible factor for hBD-2 induction further, we tried to determine 
known genes that code for surface expressed or secreted proteins. Since the whole genome 
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of E. coli Nissle has been partially sequenced (Grozdanov 2004; Sun 2005) some differ-
ences between this strain and other non-pathogenic or pathogenic bacteria contributing to 
its successful competition and lack of virulence traits are known. The genes for known 
fitness factors, distinct from other strains, were therefore deleted to evaluate their rele-
vance for hBD-2 expression. Flagellin, the flagella filament structural protein, triggers na-
tive immune responses. Flagellins from Salmonella typhimurium (Eaves-Pyles 2001; Ha-
yashi 2001) enteroaggregative E. coli (Steiner 2000) as well as P. aeruginosa (DiMango 
1995) have been shown to stimulate epithelial cells to express interleukin-8 (IL-8), nitric 
oxide (Eaves-Pyles 2001), and human beta-defensin 2 (Ogushi 2001). Further, the secre-
tion of flagellin into bacterial culture supernatants has been examined. Hence, we might 
expect flagellin from E. coli Nissle to be present in the supernatant, possibly playing a role 
as hBD-2 inducer.  
 
It has been also reported, that gram-negative H. pylori were able to activate NF-κB in 
epithelial cells by their type IV pilus secretion system (Naumann 2000). E. coli Nissle ex-
hibits two different type II secretion apparatus (Sun 2005); however this kind of secretion 
system functions only in live bacteria, still the supernatant of the heat inactivated bacteria 
might contain immunostimulatory pili or adhesins. Further, a recent study has demon-
strated that Pseudomonas aeruginosa IV pilus was necessary to activate host genes in in-
fected epithelial cells (Ichikawa 2000).  
 
Interestingly, among the constructed deletion mutants only flagellin-negative mutants 
turned out to have a diminished capacity for hBD-2 promoter activation. Complementation 
of the ΔfliC and ΔflgE mutation in the mutant strains by addition of the cloned fliC and 
flgE genes restored the ability to normal hBD-2 induction. This strengthens the proof that 
this bacterial component alone already exhibits a strong defensin-stimulating trait. Similar 
results were obtained by Reed et al (2002) who demonstrated that a ΔfliE-deficient S. ty-
phimurium mutant failed to secrete flagellin and lacked any surface assembly of flagellae. 
Complementation of the mutant strain also recovered the wild-type phenotype and elicited 
a proinflammatory response in host cells. Since fliE has been shown to interact with the 
flagellar hook protein flgB, a component of the basal body, it is thought to be required for 
the export of flagellar hook components (Minamino 1999, Minamino 2000). In T84 cells, 
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ΔfliC mutants of enteropathogenic E. coli induced significantly smaller amounts of IL-8 
than the wild-type strains. Complementation restored the IL-8 inducing capacity of EPEC 
flagellin (Zhou 2003). 
 
Despite the convincing results described above we cannot exclude that flagellin acts in 
concert with other molecules, which may also be essential for proper hBD-2 induction. 
Thus, we had to prove next, whether isolated flagellin, seperated from any potentially, syn-
ergistically acting molecules of the bacteria, would be capable to induce hBD-2 efficiently. 
Otte et al (2005) have reported that in comparison to other TLR ligands such as pepti-
doglycan, lipotaichonic acid or LPS only flagellin exposed the capacity to induce signifi-
cantly the expression of the antimicrobial peptides hBD-2, LL-37 and RNase7. Isolation of 
the E. coli Nissle flagellin by previously reported methods revealed a unique protein of 
60.81 kD as determined by mass spectrometry which was stainable by anti-H1 flagellin 
antiserum. The isolated protein was able to induce hBD-2 in a dose-dependent fashion fur-
ther substantiating that flagellin alone is a sufficient stimulant. As reference served Salmo-
nella flagellin which was also detectable with the anti H1-flagellin antiserum. However, 
the missing negative pathogenicity of E. coli Nissle, favours positive effects by this strain 
rather than by Salmonella.  
 
Despite some diversity in glycosilation degree and serotype of flagellins isolated from dif-
ferent bacteria, all proteins were detectable by H1 antiserum in the Western blot. This sero-
logical cross-reaction might be explained by the remarkable conservation of the sequences 
that mediate filament assembly, which indicates that all bacterial flagellins are likely to be 
packed into filaments in a comparable way (Beatson 2006). The band size of the uropatho-
genic E. coli CFT073∆hly flagellin in the Western blot differed compared to the band of E. 
coli Nissle flagellin, despite their flagellin serotype identity, possibly due to post-
translational modifications i.e. glycosilation. Whether surface differences are the cause for 
the determined reduced hBD-2 inducing activity of CFT073∆hly H1-flagellin compared to 
that of E. coli Nissle has to be further investigated. 
 
Addition of anti-H1 to Caco-2 cells was able to suppress hBD-2 induction by isolated flag-
ellin up to 50 %. Since we had used a polyclonal H1-flagellin antibody instead of a mono-
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clonal antibody, the concentration of specific anti-H1 antibodies was too low to bind all 
flagellin. Consequently, the abrogation of flagellin induced hBD-2 induction was incom-
plete. We conclude that flagellin is the responsible factor of E. coli Nissle mediated hBD-2 
induction in Caco-2 cells.  
 
The role of flagellin in the development of IBD might also be an important subject for fur-
ther investigation in this context. Previous studies suggest that bacterial flagellin is a 
dominant antigen in some patients with CD and mutations of innate receptors increase sus-
ceptibility to IBD (Maeda 2005, Lodes 2004). An aberrant innate response to unknown 
bacterial antigen has been proposed as a contributing factor in IBD. Since human colonic 
intestinal epithelial cells are hyporesponsive to LPS, bacterial flagellin might be an impor-
tant inducer of proinflammatory response in IEC´s in the colon. In a study from Subrama-
nian et al (2006) mucosal E. coli isolates from CD, UC and Colon cancer patients were all 
capable of inducing IL-8 release in colon epithelial cells, not only by the whole organism 
but also by the bacteria-free supernatant. Protease and leukocyte elastase pretreatment 
abolished the IL-8 response, which suggested a role for E. coli flagellin in mediating IL-8 
secretion. Interestingly, ultracentrifugation of the supernatant from E. coli showed that 99 
± 0.5 % of the IL-8 stimulating activity sedimented with the outer membrane vesicle frac-
tion, which contained flagella. Pretreatment with an anti-flagellin antibody blocked IL-8 
secretion by 50 ± 19 % compared to untreated supernatant. Centrifugal membrane filtration 
of the supernatant revealed that 70 ± 30 % of the IL-8 release was in response to compo-
nents > 30 kDa. Flagellin might hence induce the onset of inflammation in IBD. 
 
The role of flagellin (fliC) in stimulating the proinflammatory response through TLR5 re-
ceptors has been reported (Gewirtz 2001, Hayashi 2001). The signal of E. coli Nissle flag-
ellin might also be transmitted by TLR5, which is expressed in Caco-2 cells, but other 
pathways may also be relevant. A recent investigation has determined that NOD2, the in-
tracellular receptor for muramyldipeptide, a fragment of bacterial peptidoglycan, is in-
volved in the induction of hBD-2 (Voss 2006). Further, flagellin from enteroinvasive E. 
coli strains activated p38, ERK and JNK MAP kinase phosphorylation and induced IL-8 
and GM-CSF release of IEC´s through NOD1 signalling (Miyamoto 2006). Since NOD1 
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has been implicated in NF-κB-mediated hBD-2 expression (Boughan 2006) E. coli Nissle 
flagellin might also induce hBD-2 via NOD1. 
Furthermore, Ren et al (2006) suggests that in macrophages which did not express TLR5, 
the murine Naip5 (neuronal apoptosis inhibitory protein 5) (Wright 2003) might be respon-
sible for flagellin recognition. In addition, Ipaf, the closest homologue of Naip, has been 
proposed as an intracellular microbial sensor involved in Salmonella initiated caspase-1 
pathway activation (Mariathasan 2004). Recently, a direct association between cytosolic 
flagellin and Ipaf mediated caspase-1 cleavage, without any contribution of TLR5 was 
reported in macrophages (Miao 2006; Franchi 2006). Whether Ipaf might also be involved 
in flagellin signal transduction in intestinal epithelial cells is questionable. However, the 
scope of the present study was the identification of the bacterial factor rather than the elu-
cidation of recognition mechanism by intestinal epithelial cells.  
 
If flagellin is the main stimulatory component of E. coli Nissle the question arises why the 
hBD-2 induction by the bacterial pellet was so much lower than by the supernatant, as the 
flagella is normally integrated in the bacterial membrane. It is well established that flagel-
lated Salmonella serovar typhimurium, grown in vitro, sheds a remarkable proportion of its 
flagellar subunits into the culture supernatant, of which fliC seems to be the most abundant 
protein under this circumstances (Komoriya 1999). Whether E. coli also sheds high con-
centrations of flagella during cultivation into the culture liquid is not known, but the heat 
treatment of our bacteria could provoke the release of the flagella into the supernatant, ex-
plaining its higher hBD-2 inducing potential. 
 
The main obstacle to engage the epithelium is the distribution of TLR´s on the cell surface. 
Several lines of evidence indicate exclusive basolateral recognition of flagella by TLR5 
(Gewirtz 2001; Gewirtz 2003) in the normal state thereby eliminating the chance of non-
pathogenic flagellates to interact with intestinal epithelial cells. This may change in cir-
cumstance of inflammation when the epithelium is already breached and the tight junctions 
are leaky. Pathogenic strains such as Salmonella with a type III secretion mechanism obvi-
ously displace flagellin directly into the cell and have the potential to invade the epithelial 
lining thereby gaining contact to basolaterally expressed TLR5. Once the TLR5 recogni-
tion has taken place, the proinflammatory epithelial response is about to start with the sub-
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sequent engagement of immune cells. However, flagellin synthesized or secreted by many 
nonpathogenic bacteria does not incude a proinflammatory response. Interestingly, E. coli 
Nissle as an apathogenic strain induces a proinflammatory response despite its lack of abil-
ity to translocate its flagellin across the epithelial membrane to a basolaterally expressed 
TLR5. Since we used undifferentiated cells for our flagellin experiments, the ligand might 
still be able to bind to TLR5 despite its exclusive basolateral expression, making a translo-
cation unnecessary for signalling. Most ligands induce TLR expression in polarized cells 
on the basolateral side whereas unpolarized cells show a different pattern. Raz (2006) 
demonstrated that the activation of apical and basolateral TLR9 induced intracellular toler-
ance in IEC´s via distinct mechanisms. He determined that apical TLR9 triggering leads to 
a lack of IκBα degradation, an inhibition of TLR9 re-stimulation and the subsequent IL-8 
production by the basolateral TLR9. Lack of apical TLR9, by a loss of polarization, facili-
tates NF-κB activation and provokes colitis. Hence, apical TLR9 activation in polarized 
cells sustains a peaceful coexistence with commensals. In contrast, another study demon-
strated an almost 3-fold greater IL-8 release after apical compared to basolateral stimula-
tion of cells with enterohaemorrhagic E. coli (Berin 2002). Nevertheless, signalling differ-
ences might similarly occur when TLR5 is activated basolaterally or apically by flagellin, 
therefore resulting in protective or inflammatory response. An increased mucosal perme-
ability during inflammatory bowel disease, could also give commensal bacteria access to 
basolateral TLR5.  
 
6.8 Outlook 
With our results of E. coli Nissle flagellin, we provide the first evidence that flagellin from 
an apathogenic, probiotic bacterial strain specifically stimulates the expression of an an-
timicrobial peptide by epithelial intestinal cells. Since this strain, interestingly, inherits 
considerable genomic identity with the uropathogenic E. coli strain CFT073∆hly it might 
mimic on the one hand its proinflammatory effects by NF-κB and IL-8 induction but on the 
other hand, it fails to cause any real inflammation in the patient. It remains to be shown, 
whether isolated E. coli Nissle flagellin exerts its defensin-stimulating effect also in vivo 
and might ameliorate human inflammatory bowel disease. In general, flagellin induces 
inflammatory processes in vivo e.g. Salmonella flagellin injected into mice elicited at 
higher concentrations a shock-like state associated with hypotension, vascular dysfunction 
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and mortality (Eaves-Pyles 2001). A recent report in DSS colitis has demonstrated an ag-
gravation by flagellin isolated from a non-pathogenic E. coli strain (Rhee 2005). Although 
this might implicate a major drawback for the use of probiotics in inflammatory bowel 
disease, E. coli Nissle has proven its efficacy in remission maintenance not in active dis-
ease.  
 
However, the administration of isolated E. coli Nissle flagellin might exert an attenuated 
immune response compared to the complete viable strain, since living bacteria exhibit still 
many unknown effects e.g. the occupation of ligand binding sites of TLR´s to prevent the 
translocation of pathogens, which cannot be executed by an isolated flagellum. Hence, an 
aflagellate E. coli Nissle strain carries still the potential to exert a range of other probiotic 
effects. 
 
Focareta et al (2006) presented another application field of probiotics for the treatment and 
prevention of cholera, in form of a molecular mimicry of the ganglioside GM1 receptor for 
cholera toxin (Ctx) expressed on the surface of a non-pathogenic E. coli strain, which was 
able to bind and neutralize more than 99 % of Ctx. In an in vivo experiment, the recombi-
nant probiotic strain protected infant mice from challenge with virulent Vibrio cholerae 
even when the probiotic was given 4 h post-challenge. 
 
E. coli Nissle flagellin mimicking pathogenic flagellin and occupying TLR5 might have 
similar effects in the prevention of pathogenic flagellin induced inflammation. Similarly, 
the construction of E. coli Nissle strains that express normal gut epithelial cell receptors for 
virulence factors might be an alternative means of preventing enteric infectious diseases in 
addition to other defined probiotic effects. Recombinant E. coli Nissle might be able to 
interfere with the interactions between for instance bacterial toxins (or adhesins) and host 
cell oligosaccharide receptors thereby interrupting a crucial step in pathogenesis. An ad-
vantage of a receptor mimic probiotic treatment would be its neutralization of virulence 
factors, without inhibiting the growth of the bacteria. Since resistance commonly occurs in 
response to a reduction in bacterial viability, the acquisition of resistance by pathogens to a 
probiotic receptor mimic is anticipated to be unlikely (Kuehn 2006).  
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Nevertheless, the hazard of an induction of autoreactive antibodies directed against these 
receptors remains. Furthermore, most pathogenic strains exhibit many different virulence 
factors, which can impossibly be neutralized by recombinant bacteria carrying only some 
of the recognizing receptors. 
 
Finally, the administration of probiotics to patients susceptible to infections might be use-
ful for prevention, since non-pathogenic strains often exhibit the metabolic capacity to oc-
cupy the same host niche as pathogenic strains. Thus, they could co-exist in the intestinal 
tract for a sufficient length of time to be therapeutic, particularly if they outnumber the 
pathogen. The necessity of a preventive administration of probiotics might be further sup-
ported by a study carried out in the IL-10 knockout mice model of IBD, where a reduced 
expression of the Paneth cell defensins cryptidin 1, 4 and 5 was determinable before any 
histological changes of colonic inflammation appeared (Inaba 2006).  
 
Thus, an induction of antimicrobial peptide expression by probiotics might be a new thera-
peutic strategy to be applied in the remission state of diseases, to strengthen the defense 
mechanisms of the intestinal tract and extend the relapse-free time. For the acute state of 
inflammatory diseases, standard treatment should still be relied on, rather than switching 
too early to a probiotic treatment. 
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Comparison of amino acid sequences of a H1 flagellin with E. coli K12, CFT073 flagellins 
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